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 Abstract 
 The purpose of this study was to evaluate the outcomes of group speech 
therapy for individuals with Parkinson Disease (IWPD) in general and to compare 
outcomes of group treatment delivered face-to-face (FtF) versus delivery via 
telemedicine (TM). Twenty-seven IWPD received group treatment based on a 
modified version of LSVT® in either an FtF or TM format. Outcome measures were 
collected pre- and post-treatment, which included vocal intensity (dB), Voice 
Handicap Index (VHI) scores, and self-ratings. Results indicated that vocal intensity 
and self-ratings of loudness significantly increased for both the FtF and TM groups. 
VHI scores and the five remaining self-ratings were not significantly improved for 
either group following treatment, although the data on all measures from the FtF 
group did show improvement. The findings of this study support the short-term 
effectiveness of FtF and TM group therapy for improving vocal intensity and 
participant self-ratings of loudness in IWPD. 
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 Introduction 
 Parkinson disease (PD) is a commonly diagnosed progressive neurological 
disorder that affects the basal ganglia and the substantia nigra in the brain 
(Hornykiewiez & Kish, 1986). PD involves a loss of nerve cells in the substantia 
nigra, and subsequently a decrease in production of the neurotransmitter dopamine. 
An imbalance between dopamine and acetylcholine is believed to be the cause of the 
motor movements associated with PD. Tremor, bradykinesia, and rigidity are three 
classic motor symptoms associated with PD (Marsden, 1984). Speech and voice 
disturbances commonly occur in individuals with PD (IWPD). In the classification 
scheme of Darley, Aronson, and Brown (1969), these speech and voice changes are 
categorized as hypokinetic in nature. Hypokinetic dysarthria is characterized 
primarily by reduced vocal loudness, monotonous speech, variable rate of speech, 
imprecise articulation, reduced stress patterns, and a harsh or breathy vocal quality 
(Canter, 1963).   
 There is no known cure for PD, although there are treatments to alleviate 
symptoms. Pharmacological treatment of PD is common. In general, PD medications 
involve the use of dopamine replenishment, dopamine receptor agonists, dopamine 
breakdown inhibitors, or anticholinergic drugs (Yorkston, Miller, & Strand, 2004). 
Whereas pharmacological treatments have been used successfully to manage the limb 
manifestations of PD, studies have indicated mixed results regarding improvement of 
PD-related speech symptoms (Brumlik et al., 1964; Cahill et al., 1998; Critchley, 
1981; Gallena, Smith, Zeffiro, & Ludlow, 2001; Larson, Ramig, & Scherer, 1994; 
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Poluha, Teulings, & Brookshire, 1998; Sanabria et al., 2001; Schultz & Grant, 2000; 
Shea, Drummond, Metzer, & Krueger, 1993; Solomon & Hixon, 1993; Stewart et al., 
1995). 
 Surgical treatments also have been developed to alleviate the symptoms of 
PD. There are three main categories of surgical treatment including lesioning 
procedures, nondestructive or augmentative procedures, and restorative techniques 
(Rascol et al., 2003). To date, there are mixed results of the efficacy of these surgeries 
for the treatment of Parkinsonian dyskinesias and motor fluctuations (Goetz, Poewe, 
Rascole, & Sampaio, 2005). In addition, some studies have reported a worsening of 
speech symptoms following surgical treatment for PD in some patients (Allan, 
Turner, & Gadea-Ciria, 1966; Jenkins, 1968; Koller, Pahwa, Lyons, & Albanese, 
1999; Matsumoto, Asano, Baba, Miyamoto, & Ohmoto, 1976; Parkin et al., 2002). 
 In addition to treatment options aimed at alleviating the symptoms of PD in 
general, treatments specifically targeted at improving voice and speech also have 
been proposed. Surgical procedures that target voice quality and loudness changes in 
PD include type I thyroplasty, arytenoid adduction, and vocal fold injection methods 
(Berke, Gerratt, Kreiman, & Jackson, 1999; Hill, Jankovic, Vuong, & Donovan, 
2003). Although these surgical procedures can be helpful for IWPD, they are not 
ideal. They are invasive and often do not have lasting effects on the voice given the 
progressive nature of PD.   
 Behavioral speech treatment also has been used as a method for reducing the 
speech and voice disturbances associated with PD; however, until the 1990s, many 
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believed that behavioral speech treatment was only marginally effective for IWPD 
because treatment often did not carry over from the clinic into the natural 
environment (Weiner & Singer, 1989). A variety of therapeutic devices to improve 
communication also have been attempted, including pacing boards, voice amplifiers, 
Delayed Auditory Feedback (DAF) and other masking devices, and biofeedback 
(Schultz & Grant, 2000); however, these devices may be inconvenient and 
generalization of results to situations in which the devices are not used may not 
readily occur.     
 Speech-language pathologists (SLPs) have attempted to directly train 
increased vocal loudness, more precise articulation, and greater pitch and loudness 
variability, among other parameters (Schultz & Grant, 2000). To date, most SLPs 
generally consider the Lee Silverman Voice Treatment® (LSVT®) to be the most 
promising method for improving the communication of individuals with hypokinetic 
dysarthria associated with PD (Yorkston, Spencer, & Duffy, 2003). LSVT® is an 
intense treatment option that focuses on increasing the volume of the voice through 
multiple repetitions of speech stimuli using increased effort from the vocal and 
respiratory systems (Fox, Morrison, Ramig, & Sapir, 2002). LSVT® has been 
demonstrated to have positive effects on vocal loudness (Ramig, Sapir, Fox, & 
Countryman, 2001c). Additionally, LSVT® also has been shown to have positive 
effects on other aspects of speech including articulation and a variety of phonatory 
measures beyond just intensity and vocal quality even though the therapy focuses 
solely on increasing loudness (Baumgartner, Sapir, & Ramig, 2001; Dromey, Ramig, 
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& Johnson, 1995; Smith, Ramig, Dromey, Perez, & Samandari, 1995). Although 
studies have demonstrated positive outcomes from LSVT®, the time-intensive nature 
of the program and the need for qualified personnel to deliver the service imposes 
limits on how many IWPD receive the therapy. Even the developers of the LSVT® 
program have recognized the need to explore other methods of delivering the service 
or altering its frequency to make LSVT® more available to those who need it 
(Spielman, Ramig, Mahler, Halpern, & Gavin, 2007). 
 Group therapy is one possible means of increasing the availability of speech-
language pathology services to improve the voice in IWPD.  Group therapy has been 
utilized successfully across a range of communication disorders in the field of speech-
language pathology (de Angelis et al., 1997; Elman & Bernstein-Ellis, 1999a; Elman 
& Bernstein-Ellis, 1999b; Goldblum, Mulder, & von Gruenewaldt, 2001; 
Heydebrand, Mauze, Tye-Murry, Binzer, & Skinner, 2005; Robertson & Thomson, 
1984; Simberg, Sala, Tuomainen, Sellman, & Ronnemaa, 2006; Williams & Dugan, 
2002). Despite documented successes using group speech or language treatment, the 
group approach may not be universally successful across disorders or treatment foci. 
At present, there are only three reports describing group voice treatment specifically 
for IWPD (de Angelis et al., 1997; Robertson & Thompson, 1984; Sullivan, Brune, & 
Beukelman, 1996).  
 Another approach to service delivery that may allow increased access by 
IWPD to behavioral voice treatment capitalizes on advances in telemedicine. With the 
use of telemedicine, more individuals can potentially receive diagnostic and 
4 
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therapeutic services from an SLP. Whereas telemedicine initially began as a 
telephone call between a client and a clinician, the use of telemedicine in the field of 
speech-language pathology has grown substantially to include audio and video 
interfacing between client and clinician (Baron, Hatfield, & Georgeadis, 2005). 
Today, telemedicine has been incorporated into clinical practice across a range of 
communication disorders and has been utilized for both evaluation and therapeutic 
purposes (Duffy, Werven, & Aronson, 1997; Hill et al., 2006; Mashima et al., 2003; 
Sicotte, Lehoux, Fortier-Blanc, & Leblanc, 2003; Theodoros et al., 2006; Theodoros, 
Russell, Hill, Cahill, & Clark, 2003). To date, there has been only one report 
regarding the use of telemedicine for SLP service delivery to IWPD who are 
interested in improving their voice (Theodoros et al., 2006).  
Advances in telemedicine and greater use and acceptance of group therapy 
within the field of speech-language pathology have occurred over the past decade. 
Although there is well documented success of LSVT® with IWPD, there are 
limitations that restrict patient access to the therapy. This study evaluated a 
therapeutic intervention with IWPD that utilized group therapy, telemedicine service 
delivery, and principles for improving vocal loudness currently utilized in LSVT®. 
The literature reviewed below covers issues regarding group therapy, telemedicine, 
and voice therapy for IWPD. An overview of PD, treatment options available (both 
those for general control of PD symptoms and those specific to voice issues), 
limitations to current behavioral treatment in this area, and attempts at increasing 
access to SLP services by using group therapy and telemedicine are reviewed.   
 Literature Review 
Overview of Parkinson Disease 
 Parkinson disease (PD) is a fairly common progressive disease of the central 
nervous system affecting both cognition and motor control (Yorkston et al., 2004). 
The disease affects the area of the brain known as the basal ganglia, specifically the 
pars compacta of the substantia nigra (Hornykiewiez & Kish, 1986). In PD, neurons 
within the substantia nigra become impaired or die; consequently, the chemical 
dopamine is no longer produced at normal levels. A balance between dopamine and 
acetylcholine in this part of the brain is crucial for coordinated function and 
movement of muscles. The many symptoms of PD begin to develop and emerge when 
roughly 60% to 70% of the cells that produce dopamine are impaired or die (Lang & 
Lozano, 1998a). 
 According to recent estimates (“National Parkinson Foundation,” 2007), both 
men and women are equally affected by PD. There are similar rates of occurrence 
across countries, socio-economic levels, and ethnicity. Currently within the United 
States, over 1.5 million Americans are diagnosed with PD. Furthermore, 60,000 new 
cases are estimated to be diagnosed each year. The average age of onset is 65 years 
old or older; however, 15% of people diagnosed with PD are diagnosed at age 50 or 
younger.   
 PD is classified into one of three etiological groups: 1) idiopathic; 2) 
secondary or acquired; or 3) Parkinsonism Plus Syndromes (Yorkston et al., 2004). 
The largest of the three is the idiopathic group. This group contains etiologies of 
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unknown or spontaneous origin and classification of idiopathic PD is done by a 
process of excluding other potential causes of the presenting symptoms. The 
secondary or acquired group contains PD etiologies that result from the use of certain 
drugs, exposure to specific toxins, or vascular lesions within the brain. The final 
group, which has the worst prognosis, is labeled Parkinsonism Plus Syndromes (PPS). 
This is a collective range of disorders with features similar to PD usually resulting in 
an early misdiagnosis as idiopathic PD. A number of diseases and conditions are 
grouped under the heading of PPS including, but not limited to progressive 
supranuclear palsy, corticobasal degeneration, and multi-system atrophy. PPS differs 
from PD because PPS is not as responsive to pharmacological treatment. 
Additionally, individuals with PPS show extra signs and symptoms beyond what 
occur in idiopathic PD.   
 Despite differences in etiology, the fundamental difficulty that people with PD 
experience is the impaired ability to automatically perform learned motor functions 
(Marsden, 1984). There are three classic symptoms that are associated with this 
inability to perform a learned motor function: tremor, bradykinesia, and rigidity 
(Yorkston et al., 2004). Tremor occurs in nearly two-thirds of  IWPD. It is often the 
initial symptom of PD and typically begins in the extremities. The tremor occurs at 
rest (i.e., “resting tremor”) and is suppressed by activity. Bradykinesia is evidenced 
by a person’s inability to begin or execute intentional sequences of movement. When 
a movement begins, it is either expressed slowly or rapidly. In the most extreme 
situation, a movement cannot be initiated at all (i.e., akinesia). Examples of 
7 
symptoms of PD that are the result of bradykinesia include reduced facial expression, 
decreased eye blinking, and reduced swinging of the arms while walking. Lastly, 
rigidity is evident as an increase in muscle tone throughout the range of movement of 
a muscle. Additionally, postural instability is also a debilitating symptom of PD that 
is frequently included as a principal feature of PD in more recent descriptions of the 
disease. People with PD often have a stooped or bent posture that results in them 
being prone to fall to one side.   
 In addition to the debilitating limb and trunk motor characteristics associated 
with PD, voice and speech impairments are common and can lead to negative 
impressions of the person with PD (Pitcairn, Clemie, Gray, & Pentland, 1990). The 
speech and voice of an IWPD is most often categorized as hypokinetic in nature 
(Darley et al., 1969). Hypokinetic dysarthria in PD is characterized by the following: 
monopitch, reduced loudness, reduced stress, prosodic changes displayed as 
inappropriate silences, short rushes of speech and variable rate, imprecise consonants, 
and a harsh or breathy voice (Canter, 1963; Darley et al., 1969). Hypokinetic 
dysarthria can affect any one or all speech subsystems (i.e., respiration, phonation, 
articulation, prosody, or resonance), so there are other speech deficits that can occur 
beyond the more common ones listed above (Schulz & Grant, 2000).  
 Hartelius and Svensson (1994) found that 70% of the 258 IWPD in their study 
self-reported speech and voice changes that they felt were associated with PD. The 
most debilitating speech or voice problem experienced by 61% of the participants was 
a weak voice. Although “weak voice” was not explicitly defined, it appeared to be a 
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reflection of reduced vocal loudness. Other reported speech and voice problems 
included the following: imprecise articulation (36%); hoarse voice (32%); difficulty 
getting started (27%); monotonous voice (17%); speech that was too slow (11%); 
tremor (10%); stuttering (9%); speech that was too fast (6%); impaired stress or 
rhythm (5%); and voice that was too nasal (4%). The results of this study based solely 
on patient report should be interpreted cautiously because a considerable number of 
IWPD lack awareness of their speech difficulties (Coates & Bakheit, 1997). In that 
case, the data from Hartelius and Svensson (1994) may represent a conservative 
estimate of the speech and voice problems that actually are present in IWPD. 
 Logemann, Fisher, Boshes, and Blonsky (1978) investigated signs of vocal 
dysfunction in 200 patients with PD. They reported that 89% of participants 
demonstrated signs of vocal change characterized by breathiness, hoarseness, 
roughness, and tremors. Lingual and/or labial articulation disorders were found in 
45% of the patients. Inappropriate speech rates were identified in 20% of participants 
and 10% of the patients were hypernasal. This study indicates that the speech deficits 
in PD can occur across speech subsystems and may occur in the vast majority of 
IWPD. 
 The phonatory system is commonly affected in PD; therefore, IWPD often 
experience voice disorders. Fox and Ramig (1997) studied vocal sound pressure 
levels (SPL) during voice and speech tasks in individuals with idiopathic PD 
compared to an age-matched control group. The PD group displayed significantly 
lower (by 2.0-4.0 dB SPL) vocal SPLs than the control group. These authors 
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concluded that the majority of IWPD experience reduced vocal loudness. Vocal 
quality can also be affected in IWPD. A breathy vocal quality in PD is the result of an 
increase in the glottic gap due to incomplete closure of the vocal folds (Perez, Ramig, 
Smith, & Dromey, 1996). The vocal qualities of hoarseness and roughness also are 
characteristic in IWPD (Ramig & Gould, 1986). Other vocal difficulties include 
deficits in vocal initiation and timing of phonation relative to other speech activities.   
 Articulation also is susceptible to degradation in IWPD.  Specifically, 
imprecise consonant articulation is characteristic of dysarthria associated with PD 
(Yorkston et al., 2004). Stop consonants are most often affected because they require 
a great amount of constriction (Ackermann & Ziegler, 1991). Imprecise consonant 
articulation could be attributed to a reduction in tongue strength and endurance that 
has been documented for IWPD (Solomon, Robin, & Luschei, 2000). Additionally, 
rigidity of the orofacial muscles in IWPD may contribute to a failure of the 
articulators to make necessary contact with the intended articulatory target; this is 
known as articulatory undershoot.   
 IWPD also have difficulty precisely controlling the prosody of their speech. 
Both faster than normal and slower than normal speaking rates have been noted. Fast 
speaking rates have been described as “rushes of speech” (Netsell, Daniel, & Celesia, 
1975). Netsell et al. (1975) reported that some IWPD had speech rates of 13 syllables 
per second indicating a faster than normal overall speaking rate, where 5.0 syllables 
per second is considered normal (Kent, Kent, & Rosenbek, 1987). In contrast, Canter 
(1963) found no significant differences in terms of speaking rates between the IWPD 
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group and the control group; however, individual differences were noted in terms of a 
slow rate of speech. The speaking rates of two IWPD were so slow that they were 
judged abnormal.   
 The respiratory system of IWPD can be affected. The respiratory pattern of 
speech in IWPD has been described as rigid (Kim, 1968) presumably due to a rigid 
chest wall (Solomon & Hixon, 1993). Solomon and Hixon (1993) found that IWPD 
produced fewer syllables on one breath than a normal control group. IWPD also may 
demonstrate a reduction in maximum phonation times, perhaps reflecting deficits in 
both the respiratory as well as the phonatory systems (Mueller, 1971).  
 Resonance deficits also have been reported for IWPD. Inadequate 
velopharyngeal closure may lead to the perception of hypernasality in IWPD (Hoodin 
& Gilbert, 1989); however, hypernasality is a less common speech change in IWPD 
compared to changes in the other speech subsystems (Schulz & Grant, 2000). 
Treatment Options Available 
General Treatments for PD 
 Pharmacological treatments. Even though PD is a well-described and 
frequently diagnosed progressive neurological disease, there is currently no known 
cure. While the search for a cure continues, researchers and healthcare providers have 
focused on the management of the symptoms of PD. Pharmacological treatments are 
the most commonly used approach in this case. 
 Due to a lack of production of dopamine within the substantia nigra, this 
results in an imbalance between the dopamine system and the acetylcholine system 
11 
(Yorkston et al., 2004). The consequences of the unbalanced systems result in an 
incoordination of the body’s movements in IWPD. Pharmacological interventions 
have been developed in an attempt to restore a balance between dopaminergic and 
acetylcholinergic transmitter systems, thus creating a reduction of the PD symptoms. 
Pharmological intervention has proven to be quite successful for a large number of 
IWPD, and for that reason, drug regimens remain a primary tool in the management 
of PD. Drug treatments can be subdivided into dopamine replenishments, dopamine 
receptor agonists, dopamine breakdown inhibitors, and anticholinergic drugs 
(Yorkston et al., 2004). 
 First introduced in 1968, L-dopa has become the preferred dopamine 
replenishment drug treatment (Schulz & Grant, 2000). L-dopa is an orally 
administered drug. When a person takes L-dopa, only a small amount of L-dopa 
crosses the blood-brain barrier and disintegrates into dopamine that is readily 
absorbed in the brain. Dopamine that is not absorbed in the brain and that is left in the 
periphery (i.e., the gastrointestinal tract) can cause side effects such as nausea and 
vomiting (Yorkston et al., 2004). Therefore, L-dopa is routinely given in combination 
with carbidopa, which prevents metabolism of L-dopa outside of the brain, thus 
reducing the side effects of L-dopa (and also preserving the length of time that the 
drug is available for metabolism in the brain). The combination of L-dopa with 
carbidopa is now prescribed from various companies under the brand names 
Sinemet®, Paracopa®, and Atamet®. Even with the success of these drugs and drug 
combinations for alleviating the motor symptoms of PD, side effects still can and do 
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occur. Side effects include a marked drug cycle of effectiveness, presence of chorea-
like movements during peak-dose levels, hallucinations, and vivid dreams.   
 The positive impacts of L-dopa based drugs on motor function of the limbs 
are generally recognized. Whether or not these dopamine replenishment drugs are 
effective at reducing or eliminating speech symptoms of PD is open to debate. 
Rigrodsky and Morrison (1970) found that speech did improve when patients took L-
dopa; however, the changes in speech production were not statistically significant and 
were not as remarkable as changes in limb and motor function. Others have reported 
that L-dopa treatment is associated with positive changes to speech. L-dopa 
administration was shown to improve articulatory functioning, specifically lip 
movement, during speech and non-speech tasks (Cahill et al., 1998). Significant 
increases in fundamental frequency and overall vocal motor function in 20 IWPD 
have been reported by Sanabria et al. (2001). Administration of L-dopa produced a 
reduction in thyroarytenoid muscle activity in IWPD, which resulted in improvement 
of voice onset and offset for speech when compared to the non-medicated state 
(Gallena, Smith, Zeffiro, & Ludlow, 2001).  
 In contrast to the studies demonstrating a positive change in speech related to 
L-dopa administration, others have not found a significant change from the 
medication and still others have raised the possibility of a negative influence on 
speech from L-dopa drugs. Critchley (1976) reported that he observed several 
instances of peak-dose dysphonia and aphonia that he felt were induced by L-dopa. 
More recently, speech breathing was studied across the drug cycle in 14 male subjects 
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with PD (Solomon & Hixon, 1993). Results of this study indicated that the drug cycle 
had no significant effect, positive or negative, on speech breathing. Additionally, the 
effects of the drug cycle on phonatory functioning were studied in two IWPD 
(Larson, Ramig, & Scherer, 1994). No significant improvements in phonatory 
function related to L-dopa medication were reported. In another study, acoustic 
features of vowel production were studied across the drug cycle in 10 subjects with 
PD, but no significant changes in speech measures as a function of the drug were 
identified (Poluha, Teulings, & Brookshire, 1998). Given the contrasting findings of 
both positive and negative effects from the drugs, and findings indicating no 
improvement in speech when taking L-dopa, a conservative conclusion would be that 
these drugs cannot be relied on to manage the speech deficits in PD. 
 Another group of drugs used for the treatment of the symptoms of PD are 
known as dopamine receptor agonists or dopamine imitators (Yorkston et al., 2004). 
These drugs seek to mimic, enhance, and prolong the effects of dopamine within the 
brain. Common drugs available are Parlodel®, Permax®, Requip®, and Mirapex®. 
Common side effects are similar to those reported for L-dopa. Dopamine agonists 
have been shown to improve limb motor symptoms associated with PD (Lieberman, 
Ranhosky, & Korts, 1997). Additionally, there has been some suggestion that 
Mirapex® may benefit speech by increasing vocal intensity (Schulz, 2002). 
 Dopamine breakdown inhibitors, more commonly referred to as MAO-B 
(monoamine oxidase-B) inhibitors, seek to slow the breakdown of dopamine in the 
brain, thereby prolonging the effects of L-dopa (Yorkston et al., 2004). This group of 
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drugs includes selegiline, commonly referred to as Deprenyl® or Eldepryl®. In a 
recent research review, selegiline was found to be non-efficacious in the prevention 
of dyskinesias in IWPD. In a study focusing on the impact of selegiline on speech, 
positive effects on respiration for speech and on articulation were noted in 10 subjects 
with moderate PD (Shea, Drummond, Metzer, & Krueger, 1993). It should be noted 
that selegiline was taken in addition to the subjects’ established drug regimen, which 
included L-dopa; however, the drug Deprenyl® taken in isolation (i.e., without 
combining it with L-dopa) did not produce any observable change in voice or 
articulation in a different study of 10 subjects with PD (Stewart et al., 1995). Another 
group of dopamine inhibitors is known as catechol-o-methyl transferase (COMT) 
inhibitors (Yorkston et al., 2004). These drugs extend the life of L-dopa by blocking 
an enzyme that seeks out and destroys dopamine within the liver and other organs. 
The drug Tasmar® is included in this category. To date, there are no reports of the 
effects of COMT inhibitors on speech in IWPD.    
 The final drug category that is used to help alleviate the symptoms of PD is 
known as anticholinergic drugs. This drug intervention is the oldest form of 
pharmacological drug treatment used for PD (Yorkston et al., 2004). Artane®, an 
anticholinergic drug, was originally introduced in 1950. The aim of anticholinergic 
drugs is to re-establish the balance between the dopamine system and the 
acetylcholine system by preventing the action of the acetylcholine (Ach). The aim of 
Ach drugs is to reduce tremor in the extremities (Schulz & Grant, 2000); however, 
significant side effects including dry mouth, blurry near-sighted vision, constipation, 
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and weakening of the bladder have served to discourage widespread use of this drug 
with the advent of other alternatives such as L-dopa (Yorkston et al., 2004). Speech 
changes related to Artane® taken for PD management have not been widely 
investigated. In one study, Artane® was shown to improve speaking rate and speech 
intensity significantly in IWPD (Brumlik et al., 1964); however, in another 
investigation, IWPD who were administered anticholinergic drugs showed only 
occasional improvement in articulation and the changes were not  sustained over time 
(Critchley, 1981).   
 In summary, some pharmacological treatments for PD have had significant 
positive impacts on motor functions of the limbs, but these drugs cannot be relied on 
to eliminate the speech changes that accompany PD. In some studies, positive 
changes to speech have occurred, but in others there were either non-significant 
changes or, in rarer circumstances, negative impacts from the medications.   
 Surgical treatments. Before the introduction of effective pharmacological 
treatments, surgical interventions were the most commonly utilized method for 
controlling the symptoms of PD (Koller, Pahwa, Lyons, & Albanese, 1999). There 
are three main categories of surgical intervention available to IWPD: 1) Lesion 
procedures such as thalamotomy and pallidotomy; 2) Nondestructive or augmentative 
procedures such as deep brain stimulation (DBS); and 3) Restorative techniques that 
focus on fetal tissue transplantation or gene therapy (Rascol et al., 2003).  To date, 
there are mixed results regarding the efficacy of these surgeries for the treatment of 
Parkinsonian dyskinesias and motor fluctuations (Goetz et al., 2005). Additionally, 
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these surgeries may have negative effects on speech and voice in IWPD (see below 
for further explanation).   
 Lesion procedures involve the use of an electric current to destroy a specific 
area of tissue within the brain that is thought to contribute to PD symptoms (Koller et 
al., 1999). Thalamotomy involves lesioning the ventrolateral thalamus (Grossman & 
Hamilton, 1993). This surgical intervention has been successful at reducing tremor 
and rigidity on the contralateral side of operation (Tasker, Lang, & Lozano, 1997). 
Additionally, it has been used successfully to treat tremor in IWPD who are currently 
resistant to the usual drug treatments (Tasker, et al., 1997); however, surgical 
procedures have been shown to have negative effects on speech in some cases. 
Unilateral thalamotomy in a person’s dominant hemisphere can result in slow speech, 
monotonous voice, decreased vocal loudness, and articulation difficulties (Allan, 
Turner, & Gadea-Ciria, 1966; Jenkins, 1968). Bilateral thalamotomy also may 
negatively affect speech by resulting in word blocks, reduced rate of speech, and 
hypophonia (Matsumoto, Asano, Baba, Miyamoto, & Ohmoto, 1976). Due to the 
negative effects of bilateral thalamotomy, this surgical procedure is not usually 
recommended, particularly when preservation of speech is essential; however, 
reduced morbidity has occurred in bilateral thalamotomy due to advances in surgical 
techniques (Koller et al., 1999). 
 A second lesioning procedure known as pallidotomy involves lesions to the 
area of the basal ganglia known as the globus pallidus internus (GPi) (Eller & Dan, 
1997). Because IWPD have over-activity in the GPi, lesioning of this area creates 
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inhibition within this area thereby reducing the symptoms of PD. Individuals with 
mild hypokinetic dysarthria who received unilateral pallidotomy have demonstrated 
improvements in both phonatory and articulatory aspects of speech (Schulz, Peterson, 
Sapienza, Greer, & Friedman, 1999). The results suggested that unilateral 
pallidotomy may improve specific aspects of speech in individuals with mild 
hypokinetic dysarthria; however, unilateral pallidotomy did not improve the speech 
characteristics of IWPD who had more severe dysarthria. Bilateral pallidotomy has 
been associated with adverse effects on speech (Koller et al., 1999; Parkin et al., 
2002). As is the case with bilateral thalamotomy, bilateral pallidotomy is rarely 
recommended due to the adverse effects on swallowing, speech, and cognition.    
 Another surgical option available for alleviating the symptoms of PD is the 
nondestructive technique known as DBS. DBS involves the use of a device similar to 
a pacemaker that is implanted just under the skin in the chest, which sends electrical 
stimuli through a subcutaneous wire from the chest to an electrode implanted in one 
of three locations: the thalamus, the subthalamic nucleus (STN), or the GPi (Koller et 
al., 1999; Rodriguez-Oroz et al., 2005). DBS helps improve limb motor functioning 
in the majority of cases (Fields & Troster, 2000); however, the impact on speech is 
less predictable. For example, bilateral DBS stimulation of the STN did decrease 
dysarthria and improved the force of articulation in 10 people with PD (Gentil, 
Garcia-Ruiz, Pollak, & Benabid, 1999). In a one-year follow-up study, there was no 
significant worsening of speech in 17 patients who underwent thalamic DBS surgery 
(Tarsy et al., 2005); however, in another study, bilateral STN stimulation did not 
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result in a functional change in speech performance in seven IWPD (Dromey, Kumar, 
Lang, & Lozano, 2000). A similar finding of no speech improvement following 
bilateral STN DBS surgery in 46 IWPD also was reported (Zhang et al., 2006). It can 
be concluded that DBS is generally successful at alleviating limb motor symptoms of 
PD, but it cannot routinely be relied on for alleviating the speech symptoms of PD; 
however, these studies suggest hemispheric effects of DBS surgery as unilateral DBS 
surgery is more effective in improving the speech (e.g., dysarthria, articulation) 
characteristics of IWPD compared to bilateral DBS surgery. Wang and colleagues 
(2006) studied speech characteristics before and after unilateral DBS surgery of the 
subthalamic nucleus in 20 right-handed subjects with advanced stages of PD to 
determine if there were hemispheric effects on speech. Ten individuals were operated 
on the right hemisphere and ten individuals were operated on the left hemisphere. 
Results of the study suggested hemisphere effects on the speech, specifically rate of 
syllable repetitions and articulatory accuracy, of the participants.  
 A final surgical option that is new and still considered experimental is fetal 
tissue transplantation, a restorative surgery. This procedure involves the implantation 
of fetal dopaminergic cells into the basal ganglia, specifically the putaman or caudate 
(Wenning et al., 1997). The underlying principle of this technique is that the 
implanted dopaminergic cells will secrete the neurotransmitter dopamine into the 
individual’s dopamine deficient brain (Kordower, Goetz, Freeman, & Olanow, 1997). 
One study reported improvements in limb motor tasks in IWPD following fetal tissue 
transplantation; however, no systematic improvements were found in the areas of 
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phonation and articulation (Baker, Ramig, Johnson, & Freed, 1997). Currently, this 
procedure is still considered an experimental technique, and is not a primary approach 
for alleviating the speech deficits in IWPD.   
 In summary, the available surgical options have been shown to be viable 
approaches to reducing the limb motor symptoms associated with PD in the majority 
of cases; however, these surgical options do not usually improve the speech 
symptoms associated with PD and in some situations can actually increase the speech 
deficits. Considering the speech outcomes related to pharmacological as well as 
surgical treatments of PD, SLPs have sought other alternatives that specifically 
address the speech and voice symptoms that accompany PD.   
Specific Treatments to Improve Speech in PD 
 Surgical treatments. Surgical options to improve speech in IWPD include type 
I thyroplasty, arytenoid adduction, and vocal fold injection methods (Berke et al., 
1999; Hill et al., 2003). All of these procedures address the phonatory changes in PD. 
Both type I thyroplasty and arytenoid adduction increase vocal fold approximation. In 
the former, a small wedge of Silastic is implanted in the larynx through the thyroid 
cartilage at the level of the vocal fold, pushing that fold toward midline. The 
arytenoid adduction procedure involves placing sutures from the muscular process of 
the arytenoids to the cricoid cartilage. This suture is pulled tight during the procedure 
to rotate the vocal process of the arytenoid, and subsequently the vocal fold itself, 
toward midline. Both of these procedures result in a decrease in the glottic gap with 
the intent of improving vocal quality.  In one study, it was reported that 13 out of 15 
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(87%) IWPD had vocal fold bowing that resulted in incomplete glottic closure during 
phonation (Blumin, Pcolinsky, & Atkins, 2004). Type I thyroplasty and arytenoid 
adduction procedures could theoretically assist in obtaining more complete glottic 
closure for IWPD, and the use has been suggested by some in the medical field; 
however, formal reports of the outcomes of such an approach have not appeared in 
the literature.      
 Injection methods involve the insertion of collagen, gelfoam, or fat directly 
into the vocal folds to improve glottal closure (Schulz & Grant, 2000). Like the 
thyroplasty and arytenoid adduction procedures, injection methods were developed 
for individuals with vocal fold atrophy, vocal fold paralysis, or bowing of the vocal 
folds. The intent of the injection is to improve vocal quality and intensity. Berke et al. 
(1999) studied the effects of collagen augmentation on the vocal folds in 35 patients 
with idiopathic PD who experienced hypophonia. The results of the study showed 
that collagen augmentation had beneficial effects of increasing vocal loudness and 
intelligibility. In another study of 12 patients with PD and other parkinsonian 
disorders who had severe hypophonia, vocal quality, intelligibility, and volume 
improved following collagen injections into the vocal folds (Hill et al., 2003). A 
positive finding from injection laryngoplasty for individuals with Parkinsonian 
hypophonia has also been reported (Sewall, Jiang, & Ford, 2006). Although injection 
methods have been shown to improve the vocal symptoms associated with PD, these 
treatments are not ideal because the treatment itself does not usually have lasting 
effects. Hill and colleagues (2003) reported benefits of collagen injection to last 
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between 7.8 and 8.5 weeks. This becomes particularly problematic when combined 
with the fact that as PD progresses, phonatory function often continues to decline, 
which may necessitate follow-up injections in order to maintain voice improvement.   
 Behavioral speech treatments. Behavioral speech therapy also has been 
utilized as a method for improving the overall communication of IWPD; however, 
until the 1990s, it was widely believed that speech therapy was only marginally 
effective at best and that improvements that did occur did not usually generalize 
outside the treatment environment (Weiner & Singer, 1989). Between the 1950s and 
1970s, many did not believe in the effectiveness of speech intervention for IWPD. In 
Sarno’s (1968) observation of over 300 patients with PD who had speech deficits, her 
impression was that speech treatment was not beneficial. Although the patients 
received a variety of speech treatments, Sarno (1968) concluded that even if speech 
gains were made within the therapy session, these did not carry over into the natural 
environment. Likewise, Allan (1970) believed that it was impossible to ever 
discharge IWPD from speech therapy due to the progressive nature of their disease, 
which prevented them from experiencing carryover outside the therapeutic 
environment.   
 A variety of therapeutic devices have been utilized as part of the speech 
therapy programs, either as a primary means of accomplishing a change in speech or 
as a supplement to the direct behavioral intervention for individuals with hypokinetic 
dysarthria (Schulz & Grant, 2000). These devices include the use of a pacing board, a 
voice amplifier, Delayed Auditory Feedback (DAF), a wearable biofeedback device, 
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and a speech masking device. A pacing board is a device that is divided into 
segments. The user moves his/her finger from one segment to another segment at a 
designated pace and attempts to match his/her speech production to this rate by 
producing one syllable per finger tap. In one case study, a pacing board successfully 
helped a severely impaired IWPD to control palilalia, a speech disorder in which parts 
of speech are repeated numerous times with an increasing rate (Helm, 1979). Pacing 
boards are not always effective after extended use. The user may develop a pattern of 
progressively more rapid tapping on the pacing board which is no longer effective in 
slowing the rate of speech. Voice amplification devices help to increase the volume of 
a person’s voice (Schulz & Grant, 2000). It has been suggested that the device may 
help individuals monitor their speech and consequently aid in improved speech 
intelligibility (Greene & Watson, 1968). A limitation of voice amplification devices 
includes amplification of imprecise articulation, a common speech characteristic of 
IWPD. Although potentially effective, both pacing boards and voice amplifiers are 
additional objects that an individual must physically carry with them to aid speech, 
limiting their convenience.   
 DAF devices have been used with IWPD in an attempt to improve overall 
speech intelligibility. A DAF device allows users to hear though headphones what 
they said ~0.2 seconds after they speak (Silverman, 2004). This auditory delay causes 
the user to speak at a slower rate, thus improving speech intelligibility in IWPD. With 
the use of a portable, body-worn device, speech intelligibility was shown to 
dramatically improve in two out of 11 subjects with PD (Downie, Low, & Lindsey, 
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1981). When the device was in use, these two subjects improved their speech 
intelligibility by reducing the rate of speech, increasing the amount of fluent speech, 
and increasing volume; however, it should be noted that the portable DAF device 
produced no benefits to the other nine subjects involved in the study. Additionally, 
the DAF device had to be used constantly to have any effect on the individual’s 
speech. There are no others studies of DAF devices for use with IWPD.  
 A single case study reported the use of a wearable biofeedback device to assist 
an IWPD in generalizing vocal loudness outside of the clinic setting (Rubow & Swift, 
1985). The device sounded an alarm if vocal loudness dropped below a certain 
threshold. Measures that were taken pre- and post-treatment showed generalization of 
treatment behaviors into his daily life while wearing the device. Specifically, 
measures of loudness, monotonous pitch, rate, stress, distortions of vowels, and 
irregular articulatory breakdowns showed improvement; however, like other devices, 
a wearable biofeedback device may physically be an inconvenience to use in normal 
daily living. 
 A final therapeutic device that has been incorporated into therapy for IWPD 
involves the use of a portable masking device. The device is based on the “Lombard 
effect” where most individuals will increase the loudness level of their voice in the 
presence of masking noise (Adams & Lang, 1992). In 10 out of 10 IWPD who 
initially had low vocal intensity, it was reported that dramatic improvements in vocal 
loudness were demonstrated while speaking with the masking noise compared to 
speaking without the masking noise. Rate of speech and speech intelligibility were 
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not positively affected. Additionally, no generalization was reported for use when not 
wearing the device.    
 Therapeutic devices for speech treatment in IWPD have been reviewed by the 
Academy of Neurologic Communication Disorders and Sciences (ANCDS; Yorkston, 
Spencer, & Duffy, 2003). The review focused on behavioral techniques utilized in 
respiratory and phonatory treatment of dysarthria. Results suggested that therapeutic 
devices can be effective treatment options to help increase loudness and intelligibility 
in individuals with dysarthria; however, results should be interpreted with caution due 
to the small number of subjects involved in the review.  
 Although some therapeutic devices have been shown to have positive effects 
on the speech of IWPD, widespread use has not occurred principally because of the 
inconvenience of having to use the device continually in order to achieve speech 
gains; therefore, over the years SLPs have sought other behavioral approaches that do 
not rely on external devices.  These other approaches have focused on altering 
prosody, respiration, articulation, and voice (Schulz & Grant, 2000). Currently, most 
of the speech-related research on IWPD, and the trend clinically, is to focus on 
increasing loudness (e.g., Lee Silverman Voice Treatment®; see below for more 
details); however, other speech treatments have been attempted.  
 It should be noted that a review of speech and language therapy for dysarthria 
in IWPD was recently completed by The Cochrane Collaboration (Deane, Whurr, 
Playford, Ben-Shlomo, & Clarke, 2001). This review revealed only three randomized 
controlled trials involving treatment of dysarthria in IWPD. Due to the small number 
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of studies included in the review, it was determined that “there is insufficient 
evidence to support or refute the efficacy of speech and language therapy for 
dysarthria in Parkinson’s disease” (Deane et al., 2001, p. 9). Regardless of the results 
of the Cochrane review, behaviorally based speech treatment strategies have long 
been used for speech intervention in IWPD.  
 One of the first behavioral speech treatments focused on respiration (Erb, 
1973). Classes were held that emphasized speech and non-speech breathing exercises. 
The classes involved three IWPD and were held for 20 to 30 minutes three times 
weekly. All three individuals improved their intelligibility, but improvements were 
inconsistent over an unspecified amount of time. More recently, respiratory treatment 
that focused on increasing lung volume and subglottic air pressure for speech in 19 
IWPD produced statistically significant increases in SPL during reading and 
perceptual self-ratings of loudness (Ramig, Countryman, Thompson, & Horii, 1995). 
Using another respiratory treatment approach, statistically significant increases in 
vocal intensity were found, but the increase was not maintained 12 months post-
treatment (Ramig, Countryman, O’Brien, Hoehn, & Thompson, 1996). Additionally, 
one other study did not show significant improvement in vocal quality in IWPD who 
completed a respiratory based therapy approach (Baumgartner, Sapir, & Ramig, 
2001). Interestingly, Smith, Ramig, Dromey and Samandari (1995) reported a 
decrease of 1.9 dB SPL from pre- to post-treatment for individuals completing a 
respiratory based treatment program. Overall, behavioral respiratory treatment has 
been attempted with mixed results in IWPD.  
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 Behavioral management of respiratory and phonatory dysfunction in 
individuals with dysarthria (not specifically restricted to IWPD) has been reviewed by 
the ANCDS (Spencer, Yorkston, & Duffy, 2003). According to this review, there is 
evidence-based support for treatment of respiratory and phonatory dysfunction in 
dysarthria. Evidence-based treatment is targeted through improving respiratory 
support for speech; increasing control and coordination of respiration and phonation; 
and improving the overall functioning of the phonatory system. Although this 
evidence does not specifically target IWPD, the evidence is relevant because 
dysarthria is common in IWPD.  
 Additional behavioral speech treatments have focused on improving the 
prosodic aspects of speech in IWPD. Scott and Caird (1983) focused on maximizing 
prosody in 26 patients with PD who received one-hour treatment sessions five times a 
week for two to three weeks. Treatment also involved the use of a visual 
reinforcement device, a light source that was voice-operated, that allowed the user to 
self-monitor aspects of speech prosody. Subjects did significantly improve their 
speech in terms of prosody and intelligibility; however, the visual reinforcement 
device appeared to only benefit those patients with severe speech disorders. Results 
of the improvement tended to regress, but some residual benefit was maintained up to 
three months.  
 Johnson and Pring (1990) also focused on prosodic aspects of speech, namely 
pitch and loudness, but used a less intense therapy schedule than Scott and Caird 
(1983). Six subjects with idiopathic PD received 10 one-hour treatment sessions over 
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the course of four weeks. At the end of the treatment period, both pitch and loudness 
parameters of speech had improved significantly suggesting that less intensive speech 
treatment can be effective for IWPD. No follow-up measures were taken; therefore, it 
is unclear whether maintenance of these gains occurred.   
 Prosody also was the main behavioral therapeutic approach for a single case 
study of one IWPD with hypokinetic dysarthria (Le Dorze, Dionne, Ryalls, Julien, & 
Ouellet, 1992). Rate of speech, mean fundamental frequency, and intonation were 
assessed. Following auditory and visual biofeedback treatment, all three aspects of 
prosody showed improvements. The subject’s prosody was considered more normal 
with greater speech intelligibility. These improvements were maintained at a 10-week 
follow-up assessment.   
 Treatment of dysarthria through prosodic interventions was recently reviewed 
by the ANCDS (Yorkston, Hakel, Beukelman, & Fager, 2007). A review of 10 
articles, with 32 total subjects, focused on treatment of dysarthria through improved 
intonation, rhythm, or rate. Results of the review suggested that adequate conclusions 
regarding treatment of dysarthria through prosodic interventions could not effectively 
be made due to the small number of studies assessed.  
 Behavioral speech treatments: Lee Silverman Voice Treatment®. The current 
focus of most SLPs working with IWPD focuses on increasing vocal loudness using 
an intensive treatment regimen. The most researched behavioral therapy of this kind 
is known as the Lee Silverman Voice Treatment® (LSVT®). The main objective of 
the treatment is to train increased loudness that will in turn increase respiratory drive 
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and increase laryngeal musculature functioning (Fox et al., 2002). There are five main 
concepts of the LSVT® treatment method: 1) Exclusive focus on the voice and vocal 
loudness; 2) Use of high-effort productions with numerous repetitions; 3) Intense 
treatment schedule of four therapy sessions (50-60 minutes each), four times a week 
for four weeks in a row with homework to be completed each day (therapy and non-
therapy days); 4) Enhance sensory awareness of increased vocal loudness and 
increased vocal effort; and, 5) Measurement of vocal behaviors.   
 In order to assess whether the outcomes of LSVT® treatment were treatment-
specific, LSVT® treatment in individuals with idiopathic PD was compared to two 
other control groups who did not receive speech or voice therapy: 1) IWPD; and 2) 
Individuals who were neurologically normal who did not have speech or voice 
disturbances (Ramig et al., 2001c). Results indicated no significant difference in 
vocal loudness from pre- to post-treatment for individuals in either of the untreated 
control groups, but significantly increased vocal loudness for those completing 
LSVT®. On average, the LSVT® treated participants had an 8 dB increase in 
loudness. Vocal loudness was maintained at a six-month follow-up exam. In an 
earlier study, Ramig et al. (1996) had documented significant improvements in vocal 
loudness following LSVT® that were maintained for 12 months in a group of 35 
individuals with idiopathic PD. Twelve-month retention of loudness gains from 
LSVT® was subsequently confirmed by Sapir et al. (2002). In this study, 
improvement in quality of voice also was maintained at the 12- month follow-up. 
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Retention of increases in vocal loudness and pitch inflection following LSVT® also 
has been reported (Ramig et al., 2001b).  
 LSVT® has been compared to respiratory-focused treatment. Ramig and 
Dromey (1996) studied the aerodynamic aspects of vocal functioning in a group of 45 
individuals with idiopathic PD. Individuals underwent either LSVT® in combination 
with respiratory treatment or respiratory only treatment. Individuals who received the 
LSVT® and respiratory combination treatment achieved an average increase of 14 dB 
SPL due to increased subglottic air pressure and improved vocal fold adduction. In 
contrast, individuals who received the respiratory treatment alone displayed an 
average decrease of 2.3 dB SPL. Ramig, Countryman, Thompson and Horii (1995) 
randomly assigned 45 individuals with idiopathic PD to either a respiratory or a voice 
and respiratory (LSVT®) treatment group. Results indicated that LSVT® was more 
effective than respiratory only treatment. The LSVT® group increased SPL in vowels 
by an average of 13.96 dB in males and 9.89 dB in females compared to the 
respiratory only treatment group where females increased SPL by an average of 1.99 
dB and males decreased SPL by an average of 3.23 dB. Overall, LSVT® appears to 
be an effective means of voice intensity treatment for IWPD (Trail et al., 2005). 
 In addition to improvements in voice intensity, LSVT® may have carryover 
effects on aspects of speech beyond phonation. In a case study of an individual with 
early-stage idiopathic PD, the LSVT® approach not only resulted in increased 
loudness, but also improved articulation even though articulation was not specifically 
targeted in therapy (Dromey, Ramig, & Johnson, 1995). Specifically, louder 
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phonation led to improvement in articulation as evidenced by increased second 
formant transitions, increased vowel duration, and greater jaw displacement, all of 
which were interpreted as having a positive impact on the speech of the subjects. The 
changes in vocal intensity and articulation were maintained at six- and twelve-month 
follow-up exams.  
 Smith et al. (1995) used laryngostroboscopic examinations to assess phonation 
with individuals who received LSVT®. Twenty-two subjects with idiopathic PD were 
randomly assigned to either an intensive combination of voice and respiratory 
treatment (i.e., LSVT®) or a respiratory only treatment. Those completing the 
LSVT® group demonstrated more complete glottal closure during phonation and a 
greater increase in vocal loudness during the production of /i/ compared to the 
respiratory only treatment. Although the authors did not focus on vocal quality, an 
improvement in glottal adduction would be expected to result in improved vocal 
quality (i.e., reduced breathy quality, if indeed, that was present). In a more recent 
study, LSVT® was compared to respiratory effort treatment to examine the effects on 
hoarseness and breathiness in 20 IWPD (Baumgartner et al., 2001). Two expert 
listeners, both of whom were speech-language pathologists, perceptually rated the 
degree of hoarseness and breathiness from voice recordings of oral reading. The 
results of the study indicated a significant reduction in both hoarseness and 
breathiness for individuals who received LSVT®. Overall, LSVT® appears to have 
widespread effects on speech that extend beyond increased vocal loudness and to 
increase speech intelligibility. According to the World Health Organization model, 
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LSVT® has been shown to have positive effects beyond the impairment level and 
extends to the activity/participation level (World Health Organization, 2001).  
 The impact of LSVT® on swallowing disorders associated with PD has also 
been considered (El Sharkawi et al., 2002). Eight individuals with idiopathic PD had 
their swallow evaluated before and after LSVT®. The results of the study were 
promising in that both tongue coordination and lateralization during chewing and 
swallowing were improved following LSVT®. Additionally, delay in triggering the 
pharyngeal swallow while drinking also was improved. Perhaps the most promising 
result of the study was that the characteristic “tongue pumping” associated with PD 
disappeared on all but the largest bolus volumes following LSVT® treatment in all 
subjects who demonstrated this behavior pre-LSVT®. This resulted in a reduction in 
oral transit time. The findings suggested that the neuromuscular control of the oral 
and pharyngeal phases, specifically the tongue and base of tongue, may be improved 
through LSVT®. 
 IWPD often are described as having a masked-like facial expression (Rinn, 
1984). LSVT® treatment also has been shown to have positive effects on facial 
expressiveness in IWPD (Spielman, Borod, & Ramig, 2003). This retrospective study 
evaluated video samples from 44 individuals with idiopathic PD. All individuals 
received LSVT® from a certified LSVT® therapist. Facial mobility (i.e., facial 
muscle activity) and facial engagement (i.e., general communicative effectiveness) 
were evaluated. The combination of these variables allowed for the evaluation of 
facial expressiveness. Facial mobility and engagement were evaluated before and 
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after LSVT® treatment from video tapes using a five-point scale where “1” 
represented minimally mobile/engaged and “5” represented extremely 
mobile/engaged. Observers’ ratings indicated more facial mobility and greater 
engagement following treatment. This suggested that LSVT® may be an effective 
approach to increase facial expressiveness in IWPD. 
 An ANCDS literature review of 16 studies involving LSVT® treatment in 
IWPD was conducted by Yorkston and colleagues (2003). Results of the review 
suggested that LSVT® treatment produces direct post-treatment gains. Additionally, 
it was suggested that there are indications for maintenance effects of LSVT® 
treatment in IWPD.  
 In addition to the beneficial effects of LSVT® with IWPD, LSVT® also has 
been applied to a variety of other neurological disorders (Fox et al., 2006). The 
LSVT® approach has shown positive outcomes with the speech deficits associated 
with Parkinsonism plus syndromes (Countryman, Ramig, & Pawlas, 1994). Vocal 
loudness and vocal quality also were improved in select individuals with multiple 
sclerosis (Sapir et al., 2001) and cerebellar ataxia (Sapir et al., 2003). In addition to 
the benefits of LSVT® with the elderly population, LSVT® also has been applied to 
the pediatric population (Fox et al., 2006). Children with Down syndrome and 
cerebral palsy were documented to exhibit improved vocal quality, vocal loudness, 
and articulatory precision. These studies provide preliminary data suggesting that 
training to improve vocal loudness through LSVT® can have beneficial effects on the 
speech systems of persons with neurological conditions other than PD.   
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 Voice and speech improvements for IWPD who receive LSVT® have now 
been documented over multiple studies for a decade; however, there are aspects of 
LSVT® that impose restrictions on its use and availability. Initially, SLPs must 
undergo specific training from the developers of the LSVT® program. Once the 
training is successfully completed, the SLP can then advertise him/herself as a 
certified LSVT® therapist and can deliver LSVT® to individuals. The LSVT® 
training and certification require a financial and time commitment on the part of the 
SLP. This may contribute to the lack of certified LSVT® SLPs in some parts of the 
country and the world. This may be particularly true in rural settings that are further 
away from large cities where LSVT® training workshops are most likely to occur. 
Even when there are certified therapists available, other barriers exist that may limit 
how many patients receive the treatment. LSVT® requires an intensive time 
commitment from both the SLP and the patient. For many practicing SLPs, 
scheduling a patient for this amount of therapy is difficult unless they are in a 
situation where they routinely have time set aside on a daily basis for LSVT® 
therapy. From the patient’s perspective there may be a number of issues regarding the 
intense therapy schedule. For example, they may not be able to do the prescribed 
regimen if they are currently working or have other commitments each day, live some 
distance from the SLP, or rely on others to transport them to therapy. Cognitive 
deficits that can accompany PD (Yorkston et al., 2004) also may pose some 
challenges to successful completion of LSVT® therapy that at least require a 
rescaling of expected therapy outcomes (Trail et al., 2005). 
34 
 These limitations have prompted many SLPs, including the developers of 
LSVT®, to search for modifications of the program in order for it to be more 
accessible. Spielman and colleagues (2007) have examined an extended version of 
LSVT® that they refer to as LSVT®-X. Twelve individuals with idiopathic PD 
received two one-hour sessions of treatment weekly for eight successive weeks. The 
total face-to-face time between the patient and the SLP was equal between traditional 
LSVT® and LSVT®-X. The main difference between the two was the amount of 
home practice, which was significantly increased for LSVT®-X. Additionally, the 
amount of time between treatment sessions was doubled in LSVT®-X. The results 
indicated that individuals who underwent LSVT®-X did have a statistically 
significant increase in vocal loudness that was comparable to traditional LSVT®.   
 The issue of treatment delivery scheduling in order to reduce some of the 
limitations of LSVT® also has been investigated (Wohlert, 2004). Eleven individuals 
with hypokinetic dysarthria secondary to PD were assigned to participate in one of 
three treatment groups with varying treatment delivery schedules: four times weekly 
for one month, two times weekly for two months, or two times weekly for one month. 
Treatment focused on increasing vocal loudness and followed the guidelines of 
LSVT® except for the schedule of treatment. All participants were assigned the same 
number of homework sessions. Results of the study showed that every participant 
displayed an increase in vocal loudness while reading a passage. These results were 
reduced at a three-month follow-up for all participants except one, but were higher 
than pre-treatment measures. The schedule of treatment did not have an effect on the 
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outcomes of the treatment. This suggested that different LSVT® schedules may have 
immediate positive outcomes. Issues regarding retention of the loudness gains over 
time for individuals completing the voice treatment on less intense schedules need to 
be investigated in more detail.  
Recent advances in technology have helped reduce some of the limitations of 
LSVT® while still providing the recommended schedule of treatment (Halpern et al., 
2004). A device known as the LSVT® Companion (LSVT®-C) is a personal digital 
assistant (PDA) that is specially designed to administer LSVT® treatment at a 
person’s home on the same schedule as would be done in face-to-face LSVT® 
therapy with an SLP. The PDA also collects data that can be used in tracking progress 
over time. Another device known as the LSVT® Virtual Therapist is a computer-
based device that acts as a surrogate therapist based on live clinical models (Cole, 
Ramig, Yan, Halpern, & Van Vuuren, 2004). The IWPD sits in front of a computer 
screen that displays an animated virtual therapist providing instruction and feedback 
for daily completion of therapy activities. Both the LSVT®-C and LSVT® Virtual 
Therapist are still under development, and data-based assessments of their 
effectiveness are not yet available. Neither of the devices is intended to replace an 
LSVT® therapist; thus, their aim is to help alleviate some of the limitations imposed 
on the strict schedule of LSVT® treatment.  
LSVT® is considered the gold standard for treatment of voice issues in IWPD 
given the strong evidence base reported in the literature. Modifications to this 
program are being attempted by the developers of the program to increase treatment 
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accessibility. Additional considerations for delivery of voice therapy to IWPD drawn 
from other areas of speech-language pathology also may provide attractive service 
delivery alternatives. These include the use of group therapy and the use of 
telemedicine technology, or a combination of the two. 
Methods to Increase Access to Speech Treatment 
Group Treatment 
 The use of group treatment within the field of speech-language pathology is 
not new. Initially, the use of group speech treatment arose out of the need for SLP 
services following World War II (Baron et al., 2005). As the number of soldiers who 
returned home from war with closed-head injuries increased, the number of clinicians 
available to provide service was insufficient; therefore, group therapy sessions were 
implemented as a way to provide speech therapy to those in need.   
Over the last 50-60 years, SLPs have used group treatment approaches across 
a wide range of communication disorders. Although significantly more research is 
needed regarding the use of a group approach for each of the specific communication 
disorder groups discussed below, the body of literature across disorder types 
generally appears to support the position that group therapy can be an effective mode 
of service delivery.  
 The group approach has been used regularly with adults who have aphasia. 
Elman and Bernstein-Ellis (1999a) studied the efficacy of group treatment in 24 
individuals with chronic aphasia. Participants were randomly assigned to an 
immediate treatment group or a deferred treatment group. Individuals received five 
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hours of group treatment weekly for four months. Group therapy focused on initiating 
conversation and exchange of information through any means possible. The results of 
the study suggested that group communication treatment in individuals with chronic 
aphasia is efficacious. Specifically, the individuals who received immediate group 
treatment had significantly higher post-treatment scores on the Western Aphasia 
Battery- Aphasia Quotient (WAB AQ; Kertesz, 1982) and the Shortened Porch Index 
of Communicative Abilities (SPICA; Disimoni, Keith, & Darley, 1980) than 
individuals in the deferred treatment group. Other studies of group aphasia treatment 
also have demonstrated positive language outcomes (Brumfitt & Sheeran, 1997; 
Wertz et al., 1981). Additionally, group treatment for individuals with aphasia also 
has been shown to result in positive psychosocial changes (Elman & Bertnstein-Ellis, 
1999b). These psychosocial changes included beneficial support of others with 
aphasia and improved language abilities.     
 Group therapy also has been utilized in the treatment of adults (Boberg, 1976) 
and children who stutter (Williams & Dugan, 2002). Stuttering modification 
treatment might be offered in this type of setting as well as psychosocial support. 
Group treatment creates a friendly environment that may motivate children and adults 
by observing the success of their peers. It also allows participants to see others with a 
shared experience.    
 Individuals who have sustained a closed head injury (CHI) also have benefited 
from group treatment (Goldblum, Mulder, & von Gruenewaldt, 2001). A five-year 
study was conducted with six individuals with a CHI who participated in a 
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conversational group for at least two years. The results of the study indicated that 
individuals who participated in the conversational group reported improvements in 
overall quality of life, increases in life participation, improved self-confidence, and 
increased assertiveness. Although additional study is needed, these results suggest 
that group therapy may have value for individuals with CHI.   
 Group speech therapy also has benefited adults who have received cochlear 
implants (CI) (Heydebrand, Mauze, Tye-Murray, Binzer, & Skinner, 2005). A study 
was conducted with 33 adults who received CIs. Group intervention was conducted 
over a two-day program with a follow-up session one month later. Group intervention 
focused on improving overall communicative functioning and improving coping 
skills. The results of the study suggested that adults who received CIs and participated 
in group therapy enhanced their communicative functioning and improved their 
coping skills. Participants reported that following group intervention, they 
experienced fewer conversational breakdowns and felt less discouraged.     
 Voice therapy also has been provided in group settings. In one report, 40 
student teachers with mild voice disorders were enrolled for study (Simberg, Sala, 
Tuomainen, Sellman, & Ronnemaa, 2006). Twenty students received voice therapy; 
20 students did not receive voice therapy and served as the control group. Those 
receiving treatment attended voice group therapy for an hour and a half once a week 
for seven weeks. There were three small groups that consisted of six to eight 
members. The results indicated that students involved in the treatment group 
displayed significant improvement in vocal quality as compared to the students who 
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received no treatment.  These results suggested that group voice therapy is an 
effective therapeutic method for treatment of mild voice disorders. Similar beneficial 
results of group voice therapy have been reported (Carding, Horsley, & Docherty, 
1999). 
 Group voice therapy also has been implemented with IWPD (de Angelis et al., 
1997). Twenty IWPD attended 13 group voice therapy sessions over the course of one 
month. Voice therapy focused on increasing vocal intensity with groups of five 
individuals per session. After a month of voice group therapy, all participants 
demonstrated an increase in vocal intensity. All participants self-reported that others 
could understand them better following completion of group voice therapy, 
suggesting that speech intelligibility or audibility had increased. There also was a 
marked decrease in monotonous speech, suggesting more variability in speech 
intonation. Additionally, there was a decrease in strained-strangled vocal quality. In 
another study of voice group treatment, 12 IWPD received an intensive form of group 
voice treatment over the course of two weeks (Robertson & Thomson, 1984). 
Therapy focused on respiration, vocal production (with focus on loudness and 
variation of pitch), articulation, rate of speech, variation of intonation, and overall 
speech intelligibility. Although the authors did not report details, they indicated that 
there were improvements in respiration, phonation, articulation, prosody, swallowing, 
facial expressiveness, and overall speech intelligibility. These results were reportedly 
maintained for up to three months. Although further study is needed, these two 
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reports indicate that group voice therapy may result in improvements in voice and 
communication for IWPD.   
 Sullivan and colleagues (1996) also utilized group speech treatment with 
IWPD. Six IWPD with hypokinetic dysarthria participated in group speech 
intervention to improve speech intelligibility. Treatment was addressed through 
increased voice projection and increased breath support. Perceptual judgments of 
loudness, appropriate pitch, and vocal tone were assessed. Results of the study 
suggested that group speech treatment was effective in improving speech 
intelligibility for five of the six participants. Additionally, these results were 
maintained for up to 10 months following intervention.  
 Group treatment studies for IWPD with dysarthria have been reviewed by the 
ANCDS (Yorkston et al., 2003). Reports have shown success at the impairment and 
activity/participation levels; however, the interventions were not easily duplicated and 
aspects of psychometric adequacy were less than sufficient. Therefore, it should be 
noted that ANCDS concluded that there was insufficient evidence of the effectiveness 
of group treatment for IWPD with dysarthria.  
 Despite the ANCDS recommendations, group treatment offers potential 
advantages over individual therapy, which makes it an attractive consideration for 
delivering voice therapy to IWPD. One obvious advantage is that the SLP may be 
able to offer the therapy to more clients at a given time, which may partially help to 
alleviate issues regarding availability of SLP services in some locales. Group therapy 
may be a cost-effective way to provide services in comparison to traditional, one-on-
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one therapy sessions (Elman & Bernstein-Ellis, 1999a). Group treatments, depending 
on how they are structured, may also have other features that are beneficial for IWPD, 
not the least of which is the opportunity to interact and perhaps derive support from 
others with a shared experience. Additionally, group therapy might encourage a more 
natural communication exchange, which would help in generalization of targeted 
communication behaviors.  
 Despite the potentially positive aspects of group communication treatment 
with IWPD, there also are some limitations. Group communication treatment requires 
a central meeting place where the SLP is located. The greatest limitation to group 
communication treatment is the proximity of IWPD to the SLP providing service. If 
individuals are not able to attend therapy at the central meeting location, this limits 
the number of individuals served. This becomes a significant possibility when trying 
to provide services to older adults with a progressive neurological disease such as PD, 
which can impose restrictions on mobility and driving (Spielman et al., 2007). If there 
is not an SLP within close proximity to the IWPD, the individual is then forced to do 
without speech therapy or travel to the nearest service provider. In rural areas of the 
United States, this may be a heavy burden on many IWPD that limits the number of 
individuals served.     
Telemedicine 
 According to the American Speech-Language-Hearing Association (2005a), 
telepractice (i.e., telemedicine) is an appropriate delivery model for diagnostic and 
treatment services provided by speech-language pathologists. Telemedicine 
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technology provides a possible solution to the problem of patient access to SLP 
services. The use of telemedicine within the medical community has been 
acknowledged for over 25 years (Baron et al., 2005). Telemedicine initially began as 
a telephone-only communication between a clinician and a client, but has since 
evolved into more sophisticated means of connecting healthcare providers and 
patients (Burgess et al., 1999). Today, telemedicine is delivered through three distinct 
models (American Speech-Language-Hearing Association, 2005b). The store-and-
forward model is the most commonly used form of telemedicine. It is the electronic 
transmission of data from one location to another through a telephone modem, a fax 
machine, or the internet. The clinician interactive model traditionally requires an 
interaction of the client and clinician; however, the client and clinician do not have to 
be in the same location. This model is accomplished through interactive 
videoconferencing. The final telemedicine model is the self-monitoring/testing model. 
This model is mainly used by clients with chronic illnesses and requires the client to 
collect and forward data to the clinician. Delivery of telemedicine is also available 
through various devices including the telephone, videophones, closed circuit 
televisions, computers with web cameras, image scanners, and various other 
apparatuses.  
Speech-language pathologists also have explored the use of telemedicine for 
diagnostic and therapeutic purposes across a range of communication disorders. The 
use of telemedicine for diagnostic services and evaluations conducted by SLPs has 
been investigated (Duffy, Werven, & Aronson, 1997). Eight patients with a wide 
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variety of speech and language disorders received diagnostic services via satellite 
consultation. The evaluations consisted of an oral mechanism examination, a motor 
speech examination, and a language examination. The patients were evaluated by a 
clinician via satellite and also by an on-site clinician to ensure reliability of the 
satellite consultations. The authors also reviewed an additional 24 previously 
recorded videotaped samples of individuals with a variety of speech and language 
disorders who had been evaluated via satellite. Furthermore, the results of another 
150 telemedicine evaluations were retrospectively examined to help identify potential 
problems with the use of telemedicine for the purpose of evaluating and diagnosing 
speech and language problems. The results of the satellite consultations showed a 
96% agreement in diagnosis between the on-site clinician and the satellite clinician. 
Patient satisfaction was high. Results of the retrospective telemedicine evaluations 
show that in only 13% of the cases (19 patients), a definite diagnosis could not be 
made. The authors interpreted the results of the study as an indication that 
telemedicine evaluations were a reliable and beneficial method of diagnostic services 
for use with patients with a wide variety of speech and language concerns. 
 Telemedicine diagnostic services also have been implemented with specific 
subgroups of speech and language disorders. A study of 10 individuals with 
dysarthria resulting from an acquired brain injury compared evaluation results from 
two different assessments: a face-to-face assessment and an online internet 
assessment (Theodoros et al., 2003). Each assessment was conducted by a different 
SLP. The results of the study demonstrated a 90% agreement level between the two 
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different assessment environments for ratings of dysarthria severity. The authors 
interpreted this as supportive of the conclusion that there is good agreement between 
FtF assessment and online assessment of dysarthria. In a similar study, 19 individuals 
with dysarthria resulting from an acquired neurological disorder were assessed 
through an internet-based telerehabilitation system and through a traditional FtF 
assessment by two different SLPs (Hill et al., 2006). The results suggested that 
assessment of motor speech disorders can be reliably completed via an internet-based 
telerehabilitation system.   
 Individuals with voice disorders have benefited from telemedicine diagnostic 
services (Moran, Reilly, de Chazal, & Lacy, 2006). A telephone-based assessment for 
diagnosis of vocal fold pathology was developed. Fifty-six neuromuscular disordered 
voice samples and 54 normal voice samples (producing the vowel /a/) were 
transmitted over the telephone to an ENT surgeon for assessment. Results showed 
that the sustained phonation could be correctly classified as either normal or as a 
neuromuscular disorder with 89.1% accuracy. Results of the study suggested that a 
telephone diagnostic system of voice disorders is a practical option for voice 
assessments.   
 Speech-language pathology telemedicine diagnostic evaluations also have 
been completed in other large-scale telemedicine projects involving teams of 
healthcare professionals (Lemaire, Boudrias, & Greene, 2001). A low-bandwidth, 
internet-based videoconferencing system was used over a period of 21 months for 
consultations with 27 male clients and 40 female clients. A variety of healthcare 
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professions, including podiatry, nursing, medicine, occupational therapy, prosthetics, 
physiotherapy, social work, orthotics, and speech pathology, participated in the 
consultations. SLPs participated in 20% of these consultations for diagnosis of a 
communication disorder. Twenty-four clients responded to a follow-up questionnaire; 
all respondents were comfortable with the telemedicine consultation and had 
confidence in the diagnosis. Although this study was not specific to just speech-
language pathology, SLPs were included on the healthcare team in the telemedicine 
project. The results appear to be supportive of internet videoconferencing for 
consultations that include the field of speech-language pathology.  
  Speech and language treatment also has been delivered via telemedicine. One 
area of treatment that has received attention is fluency. In a study of six children and 
adolescents who stuttered, participants received fluency therapy via interactive 
videoconferencing (Sicotte, Lehoux, Fortier-Blanc, & Leblanc, 2003). The 
participants received individual therapy for one-hour sessions over the course of 12 
weeks with all therapy delivered through interactive videoconferencing. An additional 
five hours of therapy was given to four out of the six participants. During a six-month 
maintenance phase, five additional one-hour sessions were conducted with each 
participant. Overall, fluency was improved for all participants. Additionally, this 
improvement was maintained at a six-month follow-up exam. The patients also 
reported positive perceptions of the telemedicine treatment.  Kully (2000) also 
reported positive satisfaction with fluency treatment delivered through a 
videoconferencing system. An adult male patient with severe developmental 
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stuttering participated in telehealth sessions. He previously completed a three-week 
intensive stuttering treatment program. The telehealth sessions were completed two 
months post-treatment and were completed as follow-up sessions to the intensive 
stuttering treatment. Both the patient and the clinician reported positive outcomes 
following the telehealth sessions. The patient reported satisfaction with the telehealth 
sessions and felt the sessions were effective at providing guidance and feedback.  
 Treatment of voice disorders through telemedicine has been examined 
(Mashima et al., 2003). Voice therapy was delivered to 51 patients who presented 
with vocal nodules, vocal edema, unilateral vocal fold paralysis, or vocal 
hyperfunction with no laryngeal pathology. Therapy was delivered individually with 
the clinician and client either in the same room, or in separate rooms with therapy 
delivered via video teleconferencing. The results of the study showed that there were 
no significant differences between the two therapy environments when comparing 
outcome measures related to vocal quality, patient satisfaction, acoustic changes, and 
change in laryngeal tissues.   
 Voice treatment for IWPD also has been delivered through telemedicine 
(Theodoros et al., 2006). Ten individuals with idiopathic PD and hypokinetic 
dysarthria received traditional LSVT® treatment via an internet-based 
telerehabilitation application with each participant completing 16 one-hour sessions 
of individual therapy. The results of the study indicated that participants significantly 
increased loudness levels by an average of 10.8 dB and increased mean pitch range 
from 157.8 Hz pre-treatment to 229.5 Hz post-treatment. Additionally, breathy vocal 
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quality was decreased. There was also an increase in pitch variability (from a mean 
rating of 2.0 pre-treatment to a mean rating of 1.2 post-treatment) and loudness 
variability (from a mean rating of 2.3 pre-treatment to a mean rating of 1.3 post-
treatment) based on perceptual ratings of speech on a five-point scale (1 = normal to 5 
= severe). All patients reported that they were satisfied with the services provided. 
This study suggests that telemedicine is an effective method for delivering LSVT® 
treatment to IWPD. Positive outcomes also have been reported when using 
telemedicine for voice treatment and diagnosis of United States military personnel 
stationed in the Far East who were audio and video linked to clinicians stationed in 
Hawaii (Mashima & Holtel, 2005).  
 Telemedicine has been used in a range of other areas including delivery of 
pediatric SLP treatment (Forducey, 2006), dysphagia evaluations (Georges & Belz, 
2006; Perlman & Witthawaskul, 2002), and speech and language evaluations in brain 
injured individuals (Brennan, Georgeadis, Baron, & Barker, 2004). In addition to 
using telemedicine for direct patient care, the use of videoconferencing capabilities 
has been demonstrated to allow a therapist practicing in a rural setting to consult with 
other therapists (e.g., speech-language pathologists, occupational therapists and 
physiotherapists) at a larger medical facility in an attempt to provide the best patient 
care for complicated cases or when the rural therapist had limited experience or 
training related to specific clients (Jin, Ishikawa, Sengoku, & Ohyanagi, 2000).  
 The field of speech-language pathology appears to be making attempts at 
further incorporating telemedicine technology to allow greater access to services, 
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particularly for individuals in rural areas, but also for those who are not highly 
mobile. At present, much of what has appeared in the literature is descriptive in 
nature to indicate how SLPs have attempted to use telepractice technology (Hill & 
Theodoros, 2002), with fewer data-based studies on the outcomes of such attempts. 
Telemedicine is a logical alternative to consider in situations where greater access to 
SLP services is needed; however, given the nature of the problems that are being 
addressed, namely that the issues involve speech and communication, it is imperative 
that the technology allows high quality audio and video transmission and that the use 
of the technology itself does not substantially disrupt how a user is communicating.  
Statement of Purpose 
 Individuals with hypokinetic dysarthria secondary to PD present with 
decreased vocal loudness that can significantly interfere with communication. 
LSVT® has proven to be a successful method for increasing loudness for IWPD; 
however, there are limitations imposed by LSVT® that makes it inaccessible to many 
individuals in need of treatment. Utilizing group therapy, rather than individual 
therapy, may be one means of increasing the number of IWPD who have access to an 
SLP. The group format also might have other advantages over individual therapy 
such as the opportunity for psychosocial support and natural opportunities for 
practicing the behaviors targeted in therapy. However, group therapy is still reliant on 
an individual patient either having access to an SLP nearby or being willing and able 
to travel to get the service. Telemedicine offers a means of further addressing the 
issue of restricted access to SLP services. Combining an adapted version of LSVT® 
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with group treatment and telemedicine may help maximize the number of IWPD who 
are able to receive speech services. However, to date, the use of group voice therapy 
for delivering services to IWPD has received limited attention with only three 
investigations of which the authors are aware (de Angelis et al., 1997; Robertson & 
Thomson, 1984; Sullivan, et al., 1996). Even less has been reported on the use of 
telemedicine to deliver speech services to IWPD (Theodoros et al., 2006). There are 
currently no studies that compare group speech therapy for IWPD delivered in a 
traditional face-to-face (FtF) format versus group speech treatment delivered via 
telemedicine (TM).   
 The purpose of this study was to compare the outcomes of IWPD who 
participated in group speech therapy delivered in a traditional FtF format to group 
speech therapy delivered through TM. The specific questions addressed in this study 
were: 
1) Was group speech treatment effective for improving the communication of 
IWPD? Specifically, following completion of the group therapy:  
a. Was there a pre- to post-treatment difference in vocal intensity? The 
hypothesis was that increases would be found for vocal intensity as 
measured by mean dB SPL. 
b. Was there a pre- to post-treatment difference in participant self-ratings 
of loudness, vocal tremor, hoarseness, monotony, intelligibility, and 
participation in conversation? The hypothesis was that participants 
would rate themselves as louder, less tremorous, less hoarse, less 
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monotonous, more intelligible, and more willing to participate in 
conversation following completion of the group therapy. 
c. Was there a difference in the degree of voice handicap that participants 
experience as determined by self-report on the Voice Handicap Index 
(VHI) compared to their pre-treatment score on the VHI? The 
hypothesis was that the difference in pre- and post-treatment scores on 
the VHI would reflect a lessening of the perceived handicap related to 
their voice. 
2) Was there a difference in the outcomes for group speech treatment delivered 
in a traditional FtF format compared to TM? More specifically: 
a. Was there a difference in the pre- to post-treatment changes in vocal 
intensity of speech when comparing the FtF and the TM groups? The 
hypothesis was that there would be no difference in the magnitude of 
change when comparing the two groups.  
b. Was there a difference in the pre- to post-treatment change scores for 
self-ratings of loudness, hoarseness, vocal tremor, monotony, 
intelligibility, and participation in conversation when comparing the 
FtF and the TM groups? The hypothesis was that there would be no 
difference in the magnitude of change between the two groups. 
c. Was there a difference in the pre- to post-treatment change scores on 
the VHI in the FtF group compared to the TM group? The hypothesis 
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was that there would be no difference in the magnitude of change 
between the two groups.  
 Subjective reports from participants regarding aspects of the groups that they 
felt were beneficial or not beneficial also were gathered. There was a variety of 
participant-related variables that were tracked such as age, age at diagnosis, current 
PD severity level, etc. These were considered when interpreting study results, but 
given the size of the subject pool, it was not possible to incorporate these into the 
study design itself. 
 Method 
Subjects 
 Two groups of IWPD participated in this study. The first group attended a 
face-to-face (FtF) voice group at the Landon Center on Aging (COA) at the 
University of Kansas Medical Center (KUMC). This group was led by student 
clinicians and speech-language pathologists from the KUMC Hearing and Speech 
Department. Individual participant information regarding gender, age, time since 
diagnosis, and medications is provided in Table 1. The group consisted of 10 males 
and six females for a total of 16 subjects. Average age was 70.9 years (sd = 11.7) with 
an average time since PD diagnosis of 12.6 years (sd = 8.8). Participants were 
recruited from the KUMC Neurology Department, as well as from healthcare 
providers in the community and local PD support groups.   
 The second group of subjects was IWPD who attended voice groups delivered 
via telemedicine (TM). Biographical and medical information on this group is 
included in Table 2. This group consisted of one male and 10 females for a total of 11 
subjects. Average age was 75.9 years (sd = 11.9) with an average time since PD 
diagnosis of 13.0 years (sd = 7.5). SLPs from the Hearing and Speech Department at 
KUMC made arrangements with local contacts in cities within the state of Kansas to 
provide the voice groups. These groups were conducted with IWPD in Coffeeville, 
Hays, and Emporia, Kansas. Recruitment for each TM group was completed 
primarily through local resources that included PD support group personnel in that  
city/region and also local neurologists. The voice group sessions were led by two 
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student clinicians from the Hearing and Speech Department who were supervised by 
a certified speech-language pathologist in the department. 
 For both the FtF and TM voice groups, the inclusion and exclusion criteria 
were identical. The inclusion criteria were as follows: 
• Older than 18 years of age. This was dictated by the nature of PD. 
• Diagnosis of PD made by a board certified neurologist. Ideally, all 
participants would have idiopathic PD in order to be enrolled in this study. 
Historically, however, the KUMC FtF group has been open to IWPD or 
Parkinsonism with varying etiologies. It would have been ideal to restrict the 
etiology of PD to help constrain possible influences of etiology on the 
therapy’s effectiveness; however, at this early stage of investigation of group 
treatment for PD, it was more practical to allow individuals with a range of 
etiologies to participate in order to increase the number of subjects enrolled in 
the study. Information on each participant’s etiology is provided in Tables 1 
and 2.  
• Physically able to participate in weekly hour and a half voice group sessions. 
This included being able to sit for the allotted amount of time, with breaks as 
needed, while participating in a variety of voice activities that involved 
increasing vocal loudness and varying pitch. Previous experience in 
conducting the groups suggested that most individuals are able to participate 
fully in this type of structured setting regardless of disease severity. This was 
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the case for all participants in this study. Participants were not excluded if 
they were in a wheelchair.   
• Cognitively able to participate in the voice group. Because cognition was not 
screened prior to group enrollment, the graduate clinicians conducting the 
groups and the supervising SLP were vigilant for indications of deficient 
cognitive functioning for group participation. In rare instances that occurred in 
the past, it was necessary to counsel an individual out of the group due to poor 
attention, memory, or other cognitive skills. This was not the case for any 
participants that were enrolled in this study.  
• Native English speakers. This inclusion criterion was screened by participant 
self-report on a history questionnaire. Observation of participation in the 
group also indicated that all participants were native speakers of English.  
Exclusion criteria are as follows: 
• Comorbid diagnosis that could contribute to speech or communication 
deficits. This included, but was not limited to stroke, Alzheimer’s disease, and 
significant respiratory disease. Participant self-report on a history 
questionnaire was used to screen for comorbidity.   
• Prior surgery that may have altered speech production. This included, but was 
not limited to resections of facial structures, tongue, pharynx, larynx, or lungs, 
cardiothoracic surgery with known damage to the recurrent laryngeal nerve, 
and significant dental procedures. The history questionnaire served to screen 
for such surgeries. 
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• Significant hearing loss that was not currently managed with hearing aids or 
other forms of management. Individuals were not considered for enrollment if 
his/her hearing loss interfered with the ability to communicate in the voice 
group. Hearing was not formally screened; however, participant self-report on 
the history questionnaire was utilized to screen for such hearing troubles. 
Based on clinical observations by the student clinicians and supervising SLP, 
hearing issues were not a significant problem for any of the participants in this 
study. Individuals in each group were observed to use hearing aids to manage 
their hearing loss. No other assisted listening devices were utilized by any 
participant.   
Gender balance within groups and age matching across groups would have 
been ideal; however, this study was planned as an assessment of a convenience 
sample of IWPD who were interested in completing a voice group program. As such, 
enrollment was not governed by gender, age, or other potentially relevant participant-
related variables (e.g., ethnicity/race, disease severity, PD etiology, etc.). 
Unfortunately, medical records were not available for many of the participants 
(particularly those in the telemedicine groups), so it was not possible to track overall 
PD disease or symptom severity. 
 Written consent was obtained from each participant prior to any data 
collection. The research team explained the study and provided a written description 
to each potential subject. Prior to agreeing to participate, each subject was given an 
ample amount of time to read the consent form and ask questions if needed. An 
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impartial witness observed this process, which was documented in writing. For the 
FtF group at KUMC, the consent process took place at the Landon COA. For the TM 
group(s), one of the research personnel traveled to the host city to obtain consent in 
person prior to data collection. A total of 14 participants consented to be in the TM 
group, but three were dropped from the study because they did not attend a minimum 
of five group sessions. A total of 24 participants consented for the FtF group, but 
eight were dropped because they did not attend at least five sessions.   
Description of the Voice Groups 
Both the FtF group at KUMC and the TM groups were based upon principles 
and activities adapted from LSVT®, and as such the focus was on increasing vocal 
loudness. The groups were not advertised as LSVT® therapy, however, because 
modifications were made to the schedule and the activities themselves in order to 
accommodate the group format and telemedicine service delivery. The format and 
focus of the FtF and the TM groups was held as consistent as possible; however, there 
were modifications to activities and instructions necessitated by use of the 
telemedicine technology.  
 Face-to-face voice group. The FtF voice group was a six-week program in 
which participants met once a week for 90 minutes. The group was led by three 
graduate student clinicians from the Hearing and Speech Department at KUMC. All 
student clinicians completed a 90-minute orientation from the supervising SLP that 
prepared them to lead the group. During this orientation, the student clinicians were 
presented with a handout informing them of the nature and characteristics of PD. The 
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focus of the group and the typical group activities utilized to achieve the goals were 
described. Student clinicians watched a DVD showing examples of previous FtF 
voice groups so that consistency was maintained in the presentation of the group 
across semesters. Data for this study were acquired across five different 6-week voice 
groups that spanned four semesters. The students leading a particular 6-week voice 
group shifted from semester-to-semester but the supervising SLP was constant. 
Student clinicians were not LSVT® certified; however, the supervising SLP was. The 
supervising clinician was present for all sessions and oversaw all aspects of the group. 
Weekly session plans were generated by the student clinicians and were submitted for 
final approval by the supervising clinician. See Appendix A for a sample lesson plan.  
The group met in a conference room at the Landon COA with participants 
sitting around three sides of a central table. Family members were allowed to attend 
the session, but generally sat back from the table and did not actively participate so 
that focus was given to the IWPD. Water and light snacks were available to all 
present. A large marker board was at the head of the table and a large screen could be 
pulled down to allow projecting items from PowerPoint or other software programs. 
Two student clinicians were present at the head of the table. One student clinician led 
the group while the second student clinician operated the computer and wrote on the 
marker board as needed. The third student clinician roamed around the group giving 
personal feedback to the participants.  
During the sessions, group activities were completed that targeted increased 
loudness with multiple opportunities for responding. At the beginning of the session, 
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participants were greeted and welcomed. Any questions the participants may have 
had were brought up at the beginning of the session. Each session followed a specific 
theme chosen by the student clinicians. All activities for the session were focused 
around the daily theme (e.g., University of Kansas history, fruits and vegetables, 
world travel, etc.). The session’s first activity consisted of voice warm-up exercises. 
One student led the group in the warm-up exercises by providing a model that 
participants imitated as a group. A second student clinician at the marker board kept 
track of the number of responses that were completed by the group. The first warm-
up exercise consisted of 15 repetitions of a sustained /a/ (five-second duration per 
trial). Ten upward pitch glides from a comfortable to a high pitch were then 
completed followed by 10 pitch glides downward (middle to low pitch). Both the 
upward and downward pitch glides were produced by the participants using a loud 
voice. The warm-ups continued as participants repeated a set of 10 short phrases (e.g., 
thank you) three times using a loud voice. The warm-up exercises concluded with 
saying ten sentences (e.g., How was your day?) three times in the loud voice. The 
functional phrases and sentences were held constant throughout the entire six-week 
session.  
Following the warm-up exercises, six to seven activities that lasted about 10 
to 15 minutes each were completed. Throughout the activities, the student clinicians 
constantly modeled talking in a loud voice and verbally reinforced the participants for 
using a loud voice. The clinicians also frequently identified when a group or 
individual response was not produced at the target loudness level. A wide variety of 
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activities were planned by the student clinicians. Examples of activities included 
hangman, cross-word puzzles, word scrambles, matching games, sentence 
completion, individual monologues, etc. During the middle of the session, or after 
three activities, a re-energizer activity was completed. The re-energizer activity 
consisted of saying five loud “ahs.” Upon completion of all of the activities, a final 
energizer activity was completed. The final energizer activity consisted of saying five 
loud “ahs” and repeating the 10 functional phrases.  
Each session was supplemented by a PowerPoint slide show for presentation 
of the stimulus material. Activities began with the participants speaking in single 
words, and progressed toward more complex sentences. Each session increased in the 
complexity of spoken responses required by the participants. Activities targeted 
functional application for participants. Student clinicians focused on maximizing the 
response rate for each participating individual. The student clinicians switched 
responsibilities throughout the session so that one student was not engaging in 
excessive voice use by leading the entire session. Furthermore, student clinicians 
were encouraged to maintain a high level of energy.  
In addition to the weekly voice group sessions, all participants were given 
“homework” activities that were to be completed at home on a daily basis. The 
homework activities were intended to establish a louder voice outside of the voice 
group environment. The homework was expected to take approximately 30-60 
minutes to complete each day. 
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Not all those IWPD who came to the weekly sessions were enrolled as 
subjects in this study. That is, enrollment in the group was not restricted to study 
participants but rather was open to any IWPD. Group size generally ranged from five 
to fifteen participants. Those IWPD who were enrolled and participated as a research 
subject did not have to pay the $20 fee that non-study participants were required to 
pay. The student clinicians were not specifically aware of who agreed to serve as a 
subject and who did not.  
The six-week session was repeated throughout the year. Some IWPD opted to 
participate in more than one six-week block; however, to be included in this study, a 
person must not have completed any prior six-week sessions.  
 Telemedicine voice group. The TM voice group was designed to replicate as 
closely as possible the FtF group. Two student clinicians were assigned to lead the 
TM group. Paralleling the FtF group, the TM group was scheduled for 90 minutes 
once a week for six consecutive weeks, and the goal was also to train increased 
loudness with multiple repetitions.  
The TM group was conducted with two student clinicians in one of two rooms 
equipped to allow a tele-link with the remote site in Kansas. In one of these rooms, 
the student clinicians sat side by side with a Logitech video camera positioned to 
capture them within the middle of the visual field of the camera. An omni-directional 
boundary microphone positioned on the table top was utilized to detect the clinicians’ 
voices. Also on the table top were a laptop computer (Dell Latitude 6160), a visual 
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presenter (ELMO EV-368), and a switching device that allowed the students to 
switch what was being projected on the screen at the remote site. 
At the remote site where the TM participants were physically present, there 
was a video screen that displayed whatever item was selected at that moment by the 
student clinicians. A Logitech video camera and boundary microphone in the room at 
the remote site allowed the clinicians at KUMC to see and hear the participants. This 
camera was under the control of the student clinicians at KUMC who used a joystick 
to pan the camera up/down and left/right, zoom in or out, and adjust focus, if they 
desired. At each remote site, a person without PD was enlisted to help with a variety 
of tasks including helping to physically set-up the remote room for each session, 
positioning and re-positioning participants as needed prior to and during a session, 
and various other activities (getting water for participants, etc.). The PD participants 
were arranged in a semicircle or in rows (usually with a table in front of them) so that 
when the camera was panned out, all participants could be viewed at the same time. 
The activities for any given week were identical for the FtF and the TM 
groups, although some modifications had to be made at times to accommodate the 
technology and TM format. For example, clinicians were able to supply the necessary 
items needed to play Bingo for individuals in the FtF voice group, but were not able 
to supply the items for the TM voice group.  
Overview of Study Design 
 All subjects participated in pre-group data collection that involved gathering 
history, voice recordings, participant self-ratings of their voice and their 
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communication, and participant report of the degree of voice handicap. Details of the 
data collection are offered below. The pre-group data collection happened within one-
week prior to the start of the voice group. Participants then completed the six-week 
voice group. Attendance at all six voice group sessions was encouraged. A participant 
was dropped from the study if he/she missed two or more sessions (i.e., they were 
allowed to miss one session and still remain in the study). Three individuals who 
consented to be in the study and attended at least one session were dropped because 
of two or more missed sessions. Participants also were dropped if they experienced a 
major change in their PD or general health within the six-week period (this was 
assessed by participant or family report or inquiry from the supervising SLP if they 
had concerns from informal observations). No subjects enrolled in the study were 
dropped because of a change in health status.  
Data Collection: Pre-Group 
 History. Each participant completed a history form (see Appendix B) that 
assessed demographics; current employment status; and prior medical, speech, and 
communication history. The form also addressed the impact of PD on daily 
functioning. The questionnaire was completed at the time of the pre-data collection. 
The participants also were allowed to complete the questionnaire at home and return 
the questionnaire to a member of the research group at the voice group the following 
week. The form took approximately 10 to 20 minutes to complete. Family members 
or research personnel were allowed to help the participant complete the form as 
needed. 
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 Participant report of voice handicap. Included with the history questionnaire 
was a copy of the Voice Handicap Index (VHI; see Appendix C). The VHI is a widely 
used paper and pencil tool to gauge the degree of handicap an individual is 
experiencing related to his/her voice. It has been assessed for various types of 
reliability (= 0.83) and validity (= 0.76; Webb et al., 2007) and is now widely used 
within the area of voice disorders (Rosen, Murry, Zinn, Zullo, & Sonbolian, 2000), 
including for IWPD (Sewall et al., 2006; Spielman et al., 2007). It consists of 30 
statements (e.g., #1. My voice makes it difficult for people to hear me) with an 
associated 5-point Likert-type scale (labels: Never, Almost Never, Sometimes, 
Almost Always, Always). The participant was asked to fill this out at home and bring 
it back to voice group or to complete it during the pre-data collection if their schedule 
allowed. The VHI took approximately five minutes or less to complete. Family 
members or research personnel were allowed to assist in the completion of the form 
as needed. 
 Participant self-ratings. Immediately before starting the voice recordings, 
participants completed a rating form that asked them about 10 aspects of their voice 
and communication (see Appendix D). These ratings were completed using a 14 cm 
visual analog scale (VAS) with anchors given toward the left and right sides of each 
line. For example, they were asked to indicate how they perceived their own 
loudness. The investigator instructed them as follows: “I want you to think about how 
loud your voice is when you talk. Indicate whether you are always loud enough, never 
loud enough, or somewhere in between by placing a mark somewhere along this line 
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[point to the VAS line for this item].” The investigator instructed them through each 
of the 10 ratings using similar instructions. This task took approximately five minutes 
or less to complete. 
 Voice recordings. Voice recordings were obtained by placing a Shure SM 100 
headset microphone on the participant and routing the microphone signal to a portable 
CD-recorder (Marantz CDR300). The audio signal was recorded onto a CD-R disc at 
44k Hz sampling rate. In order to obtain absolute dB SPL values, the headset 
condenser microphone was calibrated in the following manner per Winholtz and Titze 
(1997) prior to each subject’s recording session: 
1. The headset microphone output was routed to the CD-recorder and the 
recording input level was set. In order to set the recording input level 
appropriately, the microphone was placed on the participant’s head with 
the tip 3 cm away from the corner of the mouth. The subject was asked to 
count to 20 and read a short passage. The input level was adjusted up or 
down as needed to obtain a strong recording that avoided overloading the 
recorder as indicated by observations of the VU meter on the CD-recorder. 
Once set, the input level was not adjusted for the calibration procedure 
that follows. Additionally, the input level remained unchanged for the 
subsequent recording of the speech protocol. 
2. The microphone was removed from the speaker’s head and placed on a 
table. A tone generator was positioned with its output 3 cm away from the 
tip of the Shure SM 100 microphone. 
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3. A 400 Hz tone was played from the tone generator. A CM 140 sound level 
meter positioned 30 cm directly in front of the tone-generator and 
microphone arrangement (see Figure I) was used to measure the dB SPL 
at that distance. 
4. The output level of the tone generator was adjusted so that the CM 140 
meter registered 60 dB SPL (using C-weighting and fast-response mode). 
At that point, the microphone output from the 400 Hz tone was recorded 
onto a CD via the microphone-CD recorder arrangement. A five-second 
recording of the 400 Hz tone played at 60 dB was obtained. The tone 
generator output was then adjusted so that the CM 140 meter registered 70 
dB SPL and another five-second recording of the 400 Hz tone was 
obtained on the CD. In the later acoustic analysis, these reference tones 
were used to calculate actual dB SPL of the speech recordings obtained for 
a given speaker. 
The speech recording itself then proceeded as follows. The participant was 
seated comfortably in a quiet clinic room (the same room in which the calibration 
procedure was completed) with the headset in position. All participants completed the 
speech recording in the order outlined below.  
1. Reading Passage: The participants read the Grandfather Passage as printed in 
large font on a sheet of paper. They were allowed to read the passage silently 
to themselves prior to the recording in an attempt to limit reading errors. They  
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 Figure 1. Calibration arrangement.    
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were instructed to read the passage using their “talking” voice at a 
 comfortable pitch, loudness, and rate. 
2. Monologue: The investigator instructed participants as follows: “I need to 
listen to you talk for about a minute without me interrupting you. I’ll give you 
a topic and you can tell me about it using your usual talking voice.” The 
investigator chose a topic from a list of alternatives and offered that to the  
 participant (e.g., What did/do you do for living? Tell about your hometown, 
 etc.). 
 Sustained vowel and pitch range recordings also were obtained during this 
session but were not analyzed for this study for two reasons. There was some 
difficulty with overloading the microphone-recorder arrangement when participants 
did the sustained vowel (i.e., the audio recording was clipped because the gain was 
too high). That is, with the recorder input level set during calibration procedures 
using counting and reading, no overload occurred; however, several subjects then 
produced sustained vowels at levels that overloaded the recorder. Additionally, the 
reading and monologue productions would seem to be a closer approximation than 
sustained vowels to what an individual might typically do in terms of speech. 
Data Collection: Post-Group 
 Within two weeks of completing the voice group, participants underwent post-
group data collection. They completed the VHI, participant self-ratings, and voice 
recordings in a manner identical to that described above. In addition, they completed 
a post-therapy questionnaire (see Appendix E) that asked them to indicate their  
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thoughts on the effectiveness of the group, those aspects of the group that they liked 
or disliked, and so forth. The intent was to gather subjective comments from the 
participants that may help in the interpretation of results and may help in the redesign 
of the groups in the future. 
Measures 
 There are three categories of outcome measures that were compared within 
subjects to identify changes from before to after completing the voice group. The 
categories are: 
1. Intensity (dB SPL): Visi-Pitch IV Model 3950 was utilized to obtain measures 
of mean dB SPL from the Grandfather Passage and the monologue. The 
audio files on the CD recording from each participant was “ripped” from the 
CD using Diamond Cut 6 software (DC6 v.6.04) and saved as .wav files. Visi-
Pitch IV was then used to open each .wav file at 44.4k Hz. Using the cursor 
marking capabilities within Visi-Pitch IV, the speech samples of interest were 
bracketed for analysis as described below.  
a. Grandfather Passage: The full reading passage was displayed within 
the Diamond Cut 6 environment for editing of the waveform to 
remove pauses. Some IWPD presented with increased numbers and 
duration of pauses which lowered the mean dB if the pauses were 
allowed to remain in the sample. The intent was to compare dB during 
speech production itself. A pause was defined as any segment of the 
acoustic wave greater than 50 msec that was not a stop gap (i.e., stop 
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gaps of any length were allowed to remain in the analysis because they 
were part of the consonant being produced). Once the pauses were 
removed, the edited passage was saved and analyzed in a manner 
similar to the sustained vowel. All sentences of the passage were 
included in this analysis. 
b. Monologue: A 30-second monologue was analyzed. The monologue 
waveform was displayed in the Diamond Cut 6 environment. Pauses 
were removed as described above. With pauses removed, the first five 
seconds of the monologue was deleted and the next 30 seconds of the 
waveform was bracketed for analysis as described above. 
 In order to obtain an absolute dB value, the calibration tone recorded on the 
CD for a given speaker also was inputted into the Visi-Pitch IV environment. The 
middle two seconds of the 60 dB and the middle two seconds of the 70 dB calibration 
tones were analyzed using the “Energy” function as was done for each of the three 
samples above. The dB mean calculated by Visi-Pitch IV for the 60 dB and the 70 dB 
tones, respectively, was logged. A conversion factor was calculated to allow 
adjustment of the dB reading output from Visi-Pitch IV to be converted to an absolute 
dB value relative to the 60 and 70 dB calibration tones. 
2. Participant Self-Ratings of Voice and Communication: Digital calipers were 
used to measure the distance from the left edge of the VAS line for a given 
scale item to the slash mark on the line made by the participant. This distance 
was measured in mm to the nearest hundredth and recorded as an indication of 
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a participant’s rating for that item. Ratings ranged from 0 mm to 140 mm with 
a rating toward 0 mm indicating less impairment and a desired response. In 
total, there are 10 VAS ratings obtained from each participant pre-group and 
10 post-group; however, only six of these rating were used for analysis 
purposes (loudness, tremor, hoarseness, monotony, intelligibility, and 
participation). In a prior study, these six had been identified as ones that were 
likely to be more sensitive to changes after completing the voice group. 
3. Voice Handicap Index: The VHI Total score (TOTAL) was used in this study. 
TOTAL scores were calculated by summing the numerical values marked for 
each of the 30 items in the tool so that TOTAL scores could range from 0 to 
120 (i.e., “never” = 0, “almost never” = 1, “sometimes” = 2, “almost always” 
= 3, and “always” = 4).  A score of 0 would reflect no handicap related to the 
voice, with increasing score values reflecting increasing perception of voice 
handicap. Three subscale scores, referred to as the Physical Scale (P-Scale), 
the Functional Scale (F-Scale), and the Emotional Scale (E-Scale), also can be 
calculated from the VHI. These are simply the sum total of distinct sets of 
items on the VHI tool. For this study, only the TOTAL score was analyzed as 
the intent was to use the VHI to measure more global changes in handicap 
related to the voice.  
Statistical Considerations 
 This study was intended to assess changes that occurred within a participant as 
a function of having completed a six-week voice group and also to compare changes 
73 
across the FtF and TM formats. The first research question asked whether 
participating in a voice group had an effect on the person in terms of his/her voice, 
while the second focused on differences pre- and post-group as a function of which 
group they were in (FtF vs. TM). Rather than completing separate pre-post statistical 
tests for all variables for each of the two questions, which would unduly increase the 
number of tests run (thereby increasing the chance of Type I errors), a more 
conservative solution utilizing analysis of variance (ANOVA) was adopted. There 
were nine dependent variables of interest (dB for Reading, dB for Monologue, six 
self-ratings, and one VHI score). To assess the dB data, a 2 (GROUP: FtF v. TM) x 2 
(TIME: Pre v. Post) x 2 (TASK: Reading v. Monologue) ANOVA with subject as a 
repeated measure for the Time variable was calculated. For the other seven dependent 
variables, separate 2 (GROUP: FtF v. TM) x 2 (TIME: Pre v. Post) ANOVAs were 
computed. By evaluating the main effects of TIME, the first research question could 
be addressed (i.e., is there any difference in the various dependent variables from Pre 
to Post-therapy). By evaluating the GROUP and the GROUP x TIME interaction 
effects, the second research question could be addressed (i.e., are there differential 
effects on the variables of interest as a function of which group therapy they 
completed). The ANOVA for the dB data required the third level (TASK) to evaluate 
whether the stimulus recorded (reading vs. monologue) was of importance.  
Given the number of statistical tests run, a more conservative alpha level than 
the traditional p = .05 was used to determine statistical significance. Sharing a .05 
alpha level across the eight ANOVAs resulted in an adjusted alpha level of 0.006 
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(0.05/8) that was used as the criterion for statistical significance for any one ANOVA 
test.    
SPSS 15.0 was used for all statistical procedures. Descriptive statistics were 
calculated for each of the variables of interest, for individual groups as appropriate, or 
for the full set of participants.   
 Results 
Vocal intensity 
Means and standard deviations for vocal intensity (dB) during reading and 
monologue are presented in Table 3. The Group x Time x Task ANOVA resulted in a 
main effect of Time (see Table 4 for the full set of ANOVA results). Inspection of the 
mean dB values (groups combined and task combined) indicated that intensity was 
significantly higher post-treatment (69.92 dB) compared to pre-treatment (64.88 dB). 
The 5.04 dB change represented a 7.8% increase from the pre-treatment dB level. The 
main effect of Task also was statistically significant. The reading condition had a 
higher dB value than the monologue, regardless of group or time. The main effect of 
Group was not statistically significant. This indicated that dB did not differ between 
the FtF and TM groups in either the pre- or the post-treatment conditions for either 
reading or monologue. The FtF group demonstrated a 5.16 dB increase and the TM 
group demonstrated a 4.88 dB increase post-treatment (combining data for reading 
and monologue). None of the interaction effects were statistically significant.  
Self-ratings 
  Group means and standard deviations for the six self-ratings are presented in 
Table 5. This table also includes the percent change in each parameter from pre- to 
post-treatment, combining data from both groups. Smaller values for a given 
parameter reflect less impairment. The results of the series of six Group x Time 
ANOVAs are offered in Table 6.  
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 Table 3 
Vocal intensity means and standard deviations (SD) by group and task
Face-to-Face Telemedicine FtF & TM Combined
Pre Post Pre Post Pre Post
Reading
Mean 66.41 72.37 65.43 70.72 66.01 71.70
SD 2.70 5.27 3.58 3.29 3.06 4.57
Monologue
Mean 62.91 67.27 64.95 69.42 63.74 68.14
SD 3.10 5.85 4.12 6.50 3.63 6.10
Reading & 
Monologue
Combined Mean 64.66 69.82 65.19 70.07 64.88 69.92
SD 3.37 6.06 3.78 5.08 3.51 5.63
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 Table 4 
Group x Time x Task ANOVA results for vocal intensity (dB)
F-Value Probability Partial Eta Squared
Group 0.198 0.658 0.002
Time 32.641 0.000 0.246
Task 8.726 0.004 0.080
Group x Time 0.026 0.873 0.000
Group x Task 3.783 0.055 0.036
Time x Task 0.475 0.492 0.005
Group x Time x Task 0.048 0.828 0.000
78 
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  Table 6
Group x Time ANOVA results for the six self-ratings
Parameter F-Value Probability Partial Eta Squared
Loudness Group 0.198 0.658 0.002
Time 32.641 0.000 0.246
Group x Time 0.026 0.873 0.000
Hoarseness Group 1.921 0.172 0.038
Time 0.114 0.737 0.002
Group x Time 5.360 0.025 0.099
Intelligibility Group 6.872 0.012 0.123
Time 0.247 0.622 0.005
Group x Time 6.709 0.013 0.120
Monotony Group 1.723 0.195 0.034
Time 2.355 0.131 0.046
Group x Time 1.297 0.260 0.026
Participation Group 1.557 0.218 0.031
Time 0.068 0.795 0.001
Group x Time 2.911 0.094 0.056
Tremor Group 1.170 0.285 0.024
Time 1.297 0.260 0.026
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Group x Time 0.015 0.902 0.000
 For loudness, there was a statistically significant main effect of Time, but not 
Group. Inspection of the pre- and post-treatment mean ratings for loudness indicated 
that the groups rated themselves as significantly louder post-treatment with an overall 
change of 25.63% on the VAS. The non-significant Group main effect suggested that 
the FtF and TM groups did not differ in their pre- or their post-treatment loudness 
ratings. The Group x Time interaction effect was not statistically significant.  
 Neither the Group nor the Time main effect was statistically significant for the 
tremor ratings despite an overall 18.19% improvement for the two groups combined. 
The interaction effect was not statistically significant.  
 For hoarseness ratings, the Group and the Time main effects were not 
statistically significant. Combining the data for the two groups, there was a 13.34% 
improvement in hoarseness ratings. Although the Group main effect was not 
significant, it is noted that the FtF group ratings indicated an improvement in 
hoarseness while the TM group ratings indicated a worsening. The large degree of 
variability in the ratings (reflected in the standard deviations) presumably prevented 
the group difference from being statistically significant. The interaction effect was not 
statistically significant.  
 Monotony self-ratings did not differ as a function of Group or Time as 
indicated by non-significant main effects in the ANOVA. Inspection of the means 
indicated that there was a trend for improvement in monotony ratings (~28% change 
for the better on this parameter). Based on the pre- and post-treatment mean ratings 
per speaker group, the trend for improvement in monotony was due principally to 
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changes in the ratings from the FtF group (changed from a mean rating of ~68 to 43), 
and not the TM group (changed from 45 to 41). The interaction effect was not 
statistically significant. 
 Ratings of intelligibility also did not change as a function of either Group or 
Time. There was an overall 11.19% improvement in intelligibility ratings when 
combining data across groups. As with the hoarseness ratings, however, there was a 
difference in the direction of change in ratings for the FtF and the TM groups. The 
FtF subjects’ ratings went from ~88 to ~65 (or a 23mm change indicating improved 
intelligibility post-treatment). Conversely, the TM group ratings went from ~49 to 
~64 (a 15 point change indicating worse intelligibility post-treatment). Although 
these changes per group are in opposite directions, neither the Group nor the Group x 
Time interaction was statistically significant, again presumably because of the large 
degree of variability in ratings across subjects in both groups.  
 Finally, for participation in conversation, the main effects of Group and Time, 
and the interaction effect were not significant. Combining data for the two groups, 
there was a 10.66% improvement in participation ratings; however, as with ratings of 
hoarseness and intelligibility, the FtF group had mean ratings reflecting an 
improvement in participation while the TM group’s ratings indicated a worsening.  
 Overall, the only statistically significant finding for the participant self-ratings 
was the main effect of Time for the loudness parameter. Subjects rated themselves as 
louder following treatment. Although there were not other statistically significant 
main or interaction effects for any of the other self-ratings, there appeared to be a 
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trend for greater percent change for the better in the group mean ratings by the FtF 
subjects compared to the TM subjects. For three of the six scales (hoarseness, 
intelligibility, and participation), the TM group actually had post-treatment group 
mean ratings that suggested the TM subjects perceived themselves as worse after the 
treatment. Table 7 summarizes the mean percent changes per group for the six self-
ratings as a means of highlighting these differences between groups. 
VHI Total Score  
Means and standard deviations for VHI Total score are presented in Table 8. 
The Group x Time ANOVA resulted in non-significant main effects of Group 
(F=7.165, p=.010, partial eta squared = .128) and Time (F=1.420, p=.239, partial eta 
squared =.028); the interaction effect also was not significant (F=1.637, p=.207, 
partial eta squared =.032). Overall, the VHI Total score had a 20.71% change from 
pre- to post-treatment when data from both groups was combined and the change 
reflected a perception of less voice-related handicap following treatment; however, 
inspection of the mean VHI scores per group before and after treatment revealed that 
the FtF group had a notable 28% (but non-significant) improvement in VHI score, 
while the TM group mean scores were essentially unchanged pre- to post-treatment. 
A lack of statistical power as indicated by the small partial eta squared value is one 
possible reason for the non-significant main effect of Group. 
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Table 7
Mean percent change from pre- to post-treatment
on measures of self-ratings by group
Self-Rating Measures Face-to-Face Telemedicine
% Change % Change
Loudness 25.80% 15.16%
Tremor 21.16% 14.68%
Hoarseness 33.99% -48.18%
Monotony 36.97% 8.28%
Intelligibility 26.18% -31.80%
Participation 26.72% -32.78%
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Table 8
Descriptive statistics of VHI Total score
(SD = standard deviation)
Group Pre Post % Change
Face-to-Face Mean 51.31 37.00 27.89%
SD 22.03 20.65
Telemedicine Mean 28.40 28.91 -1.80%
SD 20.36 18.45
Combined Mean 42.50 33.70 20.71%
SD 23.87 19.83
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 Discussion 
 The purpose of this study was to compare the outcomes of IWPD who 
participated in group speech therapy delivered in a traditional FtF format to group 
speech therapy delivered through TM. The study specifically focused on whether 
group speech treatment was effective for improving the communication of IWPD and 
whether there was a difference in outcomes between the FtF group and the TM group. 
Vocal intensity; participant self-ratings of voice, speech, and communication; and 
perceived handicap related to the voice as reflected by VHI scores were the outcome 
measures of interest. 
Pre- to Post-Treatment Change in Vocal Intensity 
 Vocal intensity was increased at the post-treatment recording for both the FtF 
and the TM groups. This finding supports the short-term effectiveness of the voice 
intervention for improving vocal intensity in IWPD. Overall, vocal intensity was 
increased by ~5 dB when combining data from both groups and both speech tasks 
(reading and monologue). de Angelis et al. (1997) also have documented a significant 
increase in dB for IWPD who complete group voice therapy (FtF), but the magnitude 
of the dB increase was not reported. Greater increases in dB than found in the current 
study have been reported for IWPD who complete LSVT®. For example, Ramig and 
colleagues noted an 8 dB increase for 14 people with PD after completing LSVT® 
(Ramig et al., 2001c). Ramig and Dromey (1996) found an even greater dB change of 
14 dB, on average, for 10 people with PD who completed LSVT®. The treatment 
program completed in these prior studies was standard LSVT®, which follows a 
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more intense schedule of therapy (one-hour per day, four days a week, four weeks in 
a row) and a greater total number of treatment sessions and treatment minutes (16 
sessions totaling 960 minutes) compared to the program in the current study (1.5 
hours per day, one day a week, six weeks in a row, six total sessions, and 540 total 
minutes). It may be that the reduction in treatment frequency and treatment minutes 
are important factors that have an impact on the magnitude of the dB change that can 
be expected for IWPD engaged in speech therapy. 
One of the principal reasons cited by the LSVT® developers for its success is 
the intensity of the treatment schedule. Recently, Spielman et al. (2007) explored an 
altered LSVT® therapy schedule in recognition of the difficulty that a sizeable 
number of IWPD have in completing the prescribed regimen. Spielman et al. (2007) 
had 12 IWPD complete LSVT-X, a treatment program that paralleled LSVT®, but 
was administered in 60-minute sessions twice a week for eight weeks. The group 
demonstrated an 8 dB increase at the end of the treatment and maintained an 
approximate 7 dB increase six months later. The authors interpreted these findings as 
support for the notion that the LSVT® treatment dose could potentially be altered 
(i.e., spread out) and still result in a dB increase. Spielman et al. were cautious in 
stating that replication of their findings with additional subjects is needed before the 
efficacy of LSVT-X is strongly established. The group therapy regimen described in 
the current study could be considered an even greater reduction in the intensity of 
traditional LSVT® than what was described by Spielman et al., and this less intense 
group alternative may result in a smaller dB increase. Future studies that specifically 
87 
assess group treatment dosage will be needed to establish the relationship between 
group treatment frequency and intensity and outcome measures such as dB.     
The fact that both the FtF and the TM groups had comparable increases in dB 
post-treatment is an important finding. The use of TM to deliver speech and voice 
services is not new; however, this study represents the first attempt of which the 
author is aware of that TM has been utilized for group therapy for IWPD. The ability 
of an IWPD to access speech services may be restricted for a variety of reasons, 
including issues with mobility and driving as well as geographic distance from SLPs 
qualified to deliver the service. The fact that the 11 subjects in the TM voice group in 
the current study had a similar dB increase as the FtF group provides some 
preliminary support for using TM to broaden access to SLP services for IWPD, at 
least if the goal is to increase vocal intensity. Theodoros et al. (2006) also utilized TM 
to deliver voice therapy to IWPD, noting a mean increase of 10.9 dB following 
treatment, but the therapy was done individually (following LSVT®), not in a group. 
The dB increases in this study were noted in a standard reading passage and a 
prompted monologue. There was no attempt to document the participant’s dB in more 
spontaneous situations, either in the clinic or at the participant’s home. As such, it 
cannot be definitively stated that the dB increase is maintained outside of the clinic or 
the recording situation; however, based on both written and verbal feedback from 
participants and their significant others, there were subjective reports of louder voice 
use in functional situations from participants in both the FtF and TM groups. On the 
post-treatment questionnaire completed by the participants, 12 of 16 FtF participants 
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(75%) reported that others had made comments related to positive improvements in 
loudness. In the TM group, seven of 11 participants (63%) offered similar comments. 
Additionally, family members have verbally recounted situations or stories with the 
SLP supervisors suggesting that at least some participants have incorporated a louder 
voice into their daily life. For example, the daughter of one TM participant described 
several situations in the home setting where the IWPD used a loud enough voice that 
it could be heard throughout the house. Another reported that a cafeteria worker at the 
nursing home where she lived specifically commented on her voice and how 
“understandable” her speech was compared to prior interactions between the two 
(before starting the group intervention). 
Pre- to Post-Treatment Changes in Participant Self-Ratings 
 Only one of the six participant self-ratings of voice and communication 
changed significantly following completion of the voice group. Loudness ratings 
were significantly improved across both groups at the post-treatment data collection. 
This was not overly surprising considering that the dB data indicated that as a group, 
the participants did have an increase in their actual intensity. An additional, or 
perhaps alternative, explanation for the loudness rating change is that, via 
participation in the groups, the participants repeatedly heard the student clinicians talk 
about increasing the loudness level of their voice. This singular focus of the voice 
group was intentionally verbalized within the group setting and feedback during the 
sessions focused almost solely on vocal loudness. It may be that the participants 
internalized this focus (in fact, that was the goal), and even if there was not an 
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associated increase in dB, they may have rated themselves as louder knowing that 
was the intended goal.  At this time, confirmation of an increase in perceived 
loudness by independent listeners has not been obtained for the current set of 
participants. Such information will be important as another means of judging the 
group voice treatment outcomes. Archived recordings from pre- and post-treatment 
data collection are available and plans are underway to gather the listener data.  
 Participants rated several other aspects of their speech and communication 
besides loudness. While loudness is perhaps the most obvious parameter to have 
subjects rate because it is the primary focus of the group, reports about LSVT® have 
suggested that a number of other aspects of speech might also change when IWPD 
work solely on increasing loudness. For example, Dromey and colleagues noted 
improvement in articulation as indicated by acoustic data on vowel characteristics and 
second formant trajectories following completion of LSVT® (Dromey et al., 1995). 
Similarly, a reduction in perceived hoarseness and breathiness in IWPD following 
completion of LSVT® has also been documented (Baumgartner et al., 2001). 
However, in the current study, there was no significant change in the ratings that 
participants offered for hoarseness, monotony, intelligibility, tremor, or participation 
in conversation. The lack of change in these parameters is in contrast to changes in 
similar features reported in other studies of group therapy for IWPD. For example, de 
Angelis et al. (1997) reported significant improvements in self-rated intelligibility, 
monotony, and strained-strangled voice quality. Robertson and Thomson (1984) did 
not report details of the assessment procedure in their group therapy investigation of 
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IWPD, but did note improvements in phonation, articulation, and prosody at the end 
of the group treatment regimen. Sullivan and colleagues (1996) suggested that group 
speech treatment was effective for improving speech intelligibility. 
Perhaps the simplest explanation for the change in only the loudness rating in 
the present study is that the group treatment only targeted increased loudness and not 
any of the other aspects of speech that were addressed on the self-rating measure. The 
group approach may be less effective than LSVT® at influencing other aspects of 
speech production; however, caution should be taken when discussing the group 
approach since the intensity of the current study (six total sessions) was so much less 
than LSVT® (16 total sessions). The reason for additional changes besides loudness 
following completion of one treatment program, but not the other, is not readily 
apparent. One possible explanation is that there is not as much talk-time in the group 
setting compared to the traditional LSVT® setting.  
Although only the loudness rating was statistically significantly changed, each 
of the other five parameters did change in a direction suggesting improvement post-
intervention when the ratings for the FtF and the TM subjects were considered 
together; however, it is clear from inspection of the pre- and post-treatment means for 
the FtF and TM groups that the FtF participants reported improvements on more of 
the parameters (all six in fact) than the TM participants. The TM participant ratings 
reflected improvements for three of the six (loudness, tremor, and monotony). The 
remaining three parameters were rated by the TM group as being worse following the 
intervention; this included ratings for hoarseness, intelligibility, and participation in 
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conversation. A lack of statistical power as indicated by the small partial eta squared 
values is one possible reason a difference in the self-ratings (except loudness) was not 
detected.  
Possible reasons for a worsening of ratings in the TM group should be 
considered. Before doing so, one should not over-interpret this apparent difference in 
how the two groups responded on the self-rating scales prior to and after treatment. 
Recall that there were no statistically significant group differences between FtF and 
TM on any of the self-ratings and none of the Group x Time interaction effects were 
significant. With that caution in mind, however, a primary focus of this study was to 
evaluate whether FtF and TM service delivery results in similar outcomes. At a 
minimum, the discrepancies in the direction of change on the ratings from the two 
groups raise the possibility that the TM individuals have less positive outcomes from 
the patient’s perspective. One possibility to consider is whether some members of the 
TM group had a worsening of their PD over the six-week time period of the study, 
although this seems unlikely. None of the participants volunteered information during 
the course of the study or at its conclusion that their PD had substantially worsened. 
Additionally, neither the student clinicians nor the SLP supervisors noted any 
substantial change in behaviors or abilities consistent with a substantial worsening of 
the disease. Also, PD does not typically present with rapid disease progression in 
most cases, so it seems unlikely that there would be a noticeable change within six 
weeks.  
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A second explanation for the worsening of ratings for the TM group is that 
some members of the TM group may have substantially altered their internal referent 
for how severe they perceived their speech/communication to be as a function of 
participating in the treatment and/or from being around other participants with PD on 
a regular basis. That is, at the pre-data collection session they may have rated 
themselves as having fairly limited problems or difficulties, but once they focused on 
their communication for six weeks and had a chance to see a range of speech abilities 
from other members in the group, they may have altered how they perceived 
themselves on any given parameter. In future studies, providing the participants with 
their pre-treatment ratings should be considered. It may have been the case that some 
individuals shifted their use of the rating scales from pre- to post-treatment and 
provision of the earlier rating may help in that regard. Additionally, there were some 
individuals in the TM group who rated themselves pre-treatment as having no deficit 
(a rating of 0) on some scales; this did not happen for any of the 16 FtF participants. 
Interestingly, those TM participants who rated themselves pre-treatment as having no 
deficit on a particular speech parameter always rated themselves as having a deficit 
on the parameter post-treatment. It is possible that a participant may simply have 
misunderstood how the scale was to be completed at the first data collection session, 
although an investigator was always present with them as they filled out the scales 
and this did not seem to be the case. Finally, it may have been the case that ratings 
were taken on either a particularly “good” day pre-treatment or perhaps a “bad” day 
post-treatment for some individuals. Participants were asked to consider how they 
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have performed over the past several days when they responded on the self-rating 
scales, but it is not possible to know whether they really did so or not.   
Pre- to Post-Treatment Changes in VHI Scores 
The statistical analysis indicated that the VHI score did not change from pre- 
to post-treatment, even though the percent improvement in VHI score was slightly 
over 20% for the FtF and TM groups combined. The lack of a statistically significant 
change at the post-recording was somewhat surprising given 20% change and the 
comments from participants on the post-treatment questionnaire that suggested they 
felt the group was beneficial. A lack of statistical power as indicated by the small 
partial eta squared value is one possible reason that a difference was not found.  
Although the FtF and TM groups did not differ statistically on their VHI 
scores, the group means suggest a difference that seems clinically relevant. The FtF 
group had a notable improvement on the VHI (28%) suggesting that they perceived 
some change in the degree of voice handicap even though this did not reach statistical 
significance. The percent change in VHI score for the FtF participants in the current 
study is comparable to prior research findings with IWPD who completed LSVT®. 
Spielman et al. (2007) reported a 25% decrease in VHI Total score (i.e., less 
perceived handicap) in a group of IWPD who completed an extended version of 
LSVT® (known as LSVT-X).   
The VHI mean scores for the TM group were essentially unchanged from pre- 
to post-treatment. There is not a ready explanation for this lack of change. One 
possible explanation could be related to memory problems for the TM group. The TM 
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group may not have remembered how they filled out the pre-treatment form when 
they were completing the post-treatment form. In future studies, providing the 
individuals with their pre-treatment ratings should be considered. It does appear that 
the TM group started off at the pre-treatment recording with a notably lower 
(indicating less impairment) mean VHI score than the FtF group, although statistically 
there was no difference between the groups at either recording time. This lower VHI 
score for the TM group at the onset of the study (and lower self-ratings on five of six 
participant self-rating scales) supports the notion that the TM group may have been 
less impaired in terms of the voice compared to the FtF group at the start of the study, 
at least based on self-report measures. It may be that the outcomes of the voice group 
intervention are dependent on the degree of voice involvement at the start of therapy. 
Those who see themselves as having more voice trouble may truly experience greater 
benefit from the group which is then reflected in self-report measures. Alternatively, 
they may simply report greater voice benefit, regardless of whether the voice changed 
substantially as a function of the intervention.  
Looking at the data for individual TM participants, there is no clear pattern or 
relation between VHI scores and the other measures of interest in this study. For 
example, one TM speaker who reported greater voice handicap after the group 
intervention also reported a worsening in five of the six self-ratings and no change in 
the loudness self-rating, but had a 6.3 dB increase in intensity. Perhaps an increase in 
intensity was not the particular kind of improvement or change that this person 
needed to facilitate his/her communication. Two other participants in the TM group 
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presented with a similar pattern (dB increased but worse VHI scores and worse self-
ratings for a majority of the self-ratings); however, there were others in the TM group 
who presented differently. For example, a few TM participants showed no change in 
VHI score, but substantial improvement in the self-rating of loudness, an increase in 
dB, and scattered improvement on the other self-ratings. Still others had an 
improvement in VHI score, dB, and loudness ratings, but worsening on all other self-
ratings. The divergent profile of results across participants may simply reflect a multi-
factorial situation in which a person’s rating of the degree of voice handicap and 
his/her self-ratings of other speech parameters is influenced by many factors, not just 
a change in dB. For some individuals, increasing dB to the extent that it was in this 
study may not have been sufficient to effect a change in more global ratings of 
speech, voice, or handicap. Of course, alternative explanations for the lack of change 
in VHI scores for the TM group should also be considered. These are essentially the 
same as those noted above for the self-ratings (i.e., worsening of PD during the study, 
individual speakers recalibrating how they view themselves once they are in the 
group, misunderstanding of the scales or items on the scales, idiosyncratic outcome of 
catching a person on a day when his/her speech was particularly good or particularly 
bad).  
Limitations and Future Directions 
 There are several limitations of the current study, many of which have been 
identified in the discussion above. The most obvious, and perhaps most significant 
limitation, is that the subject groups were fairly small, particularly the TM group. 
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Increasing the size of the groups would not only increase statistical power for 
identifying differences across groups, but it would also allow the possibility of 
subdividing the groups into potentially relevant categories to look for variables that 
might influence group treatment outcomes. For example, stratifying the groups 
according to PD disease severity, degree of voice impairment, age, gender, and so 
forth, all may be helpful in future studies attempting to determine if the intervention 
is effective and for whom it is effective.  
 Although the treatment sessions were designed to elicit frequent responses 
from group participants, detailed information about the extent of participation or 
voice usage during the sessions was not gathered. The LSVT® program is designed 
to get a high response rate from a client within a given session, although the specific 
number of responses has not been stated in descriptions of LSVT®. Frequent use of a 
louder voice is believed to be critical to the success of LSVT®. Within the group 
setting, it is possible that an individual may have less opportunity to respond 
compared to individuals enrolled in LSVT ® or an individual in the group may chose 
not to respond. Ideally, the graduate student clinicians or SLP supervisor would 
notice a “non-responder” in the group and would promptly re-engage him/her in the 
group; however, it is also possible that within the group, a person may appear to be 
responding with the target voice (i.e., louder), but it may be difficult for the clinicians 
to judge whether an individual voice within the group response was truly as loud as 
desired. That is, an individual may be responding but not in a loud voice. Future 
studies will need to consider these details and possibly manipulate them in order to 
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gauge the relative importance of these features of the group process. Preliminary data 
regarding frequency of responding and total time spent talking in the group have been 
gathered on groups run following termination of the data collection for the present 
study. Briefly, several graduate students have visited the FtF group and observed 
individual participants to measure how much talking they do during the 90-minute 
session. Using a handheld stopwatch, the mean duration of talking within a session 
was ~10 minutes (n = 13 participants observed over five sessions). In a second round 
of data collection, a tally was made of the number of responses made by individual 
participants in the FtF setting. The mean number of responses in a session was 254, or 
2.82 responses per minute. These data have not been analyzed in terms of relation to 
any of the other variables considered in the current study. Information on the TM 
group has not yet been gathered. 
Different student clinicians were used for each six-week treatment session. 
This may be another variable that should be considered in future studies. It may be 
that more experienced clinicians operate the group differently, perhaps with differing 
outcomes. Greater consistency in the leaders of the group would have helped control 
the possibility that a particular six-week session was conducted differently than 
others. Constancy in the SLP supervisor provided some measure of control over the 
way sessions were run and the quality of the treatment; however, some graduate 
clinicians are stronger than others, and one six-week session may have been 
conducted more efficiently and with better outcomes. The number of subjects drawn 
from each six-week block was relatively small, precluding a statistical comparison of 
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outcomes from one six-week session compared to another. Despite the introduction of 
possible differences in groups related to change over in graduate student clinicians, 
this situation of changing clinicians does make it all the more impressive that 
significant changes in loudness and perceived loudness were found. There is a certain 
level of ecological validity to allowing different clinicians to lead the groups as this 
parallels to some extent the situation in which different certified SLPs carry out any 
other type of treatment within the field.  
Data regarding listeners’ perceptions of the participants’ voices before and 
after treatment have not been gathered. More specifically, while the participants 
themselves indicated they were louder after treatment, it is not known whether 
independent and less biased listeners would report the same. The recordings for such 
a study are available and plans are underway to gather this information. In addition to 
having listeners’ judge loudness, it will be important also to rate other aspects of 
speech and voice such as the degree of hoarseness, tremor, monotony, and so forth 
because of the unexpected outcome in the TM group where mean participant self-
ratings suggested a worsening on some parameters after the treatment was completed. 
The current study only gathered voice recordings one-day to two weeks after 
participants completed the intervention. Future studies should assess outcomes over a 
longer time frame to determine whether the gains in dB, self-rated loudness, and 
perhaps other parameters are retained beyond the first few weeks after the conclusion 
of treatment. 
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Finally, this study does not provide any information about whether the dB 
increase noted at the post-intervention recording is truly reflective of the intensity a 
participant uses in his/her daily communication. It is possible that the majority of 
participants increased their dB during the recording (particularly post-intervention) 
because they know they can and they know that has been focused on for the prior six 
weeks in therapy; however, outside the presence of the clinic, clinicians, and 
recording equipment, an individual may not utilize a greater vocal intensity. Carefully 
designed studies that allow sampling of dB throughout an individual’s day would be 
ideal to address this issue (possibly utilizing newly available vocal monitors), but also 
reports from daily communication partners who are trained to the perceptual task 
could also be helpful in this regard.  
Conclusions 
Overall, the results of this study support the short-term effectiveness for 
improving vocal intensity in IWPD following group speech treatment. Improvements 
in dB were found for participants in both the FtF and the TM groups. The 
documented changes in dB were approximately half of the dB increase reported for 
individuals undergoing LSVT®, with differences in the schedule and intensity of 
treatment offered as the most likely explanation for the smaller dB change reported 
here. Paralleling the measured change in dB, participants in both groups rated 
themselves as being louder following completion of the treatment. These two findings 
(increased dB and perception of voice as louder), along with the anecdotal reports of 
treatment effectiveness from participants and families, are encouraging from a 
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clinical perspective. It would appear that group therapy using the schedule and focus 
of intervention described here holds promise for increasing the loudness of an IWPD 
regardless of whether the intervention is delivered FtF or via TM.  
The VHI and participant self-rating data for the FtF group showed changes in 
a positive direction even though the changes were not statistically significant due to a 
lack of statistical power as indicated by the small partial eta squared value. This trend 
for positive change in the VHI and other self-rating parameters, when combined with 
significant increases in dB and self-rated loudness, is also encouraging in terms of 
using the group speech therapy in the FtF format. The VHI and self-report data for the 
TM group format are less positive, with limited change, no change, or in some 
instances worsening of self-perceptions of voice and communication following the 
treatment. Differences in the perception of voice and communication abilities at the 
start of the study, a shifting in the use of the scale or a recalibration of how severe an 
individual perceived him/herself at the end of the study, possible memory problems, 
and a change in disease state were some of the possible reasons offered for the lack of 
change or a worsening of perceptions in the TM group after completion of the group 
therapy. Additional work will be needed to more carefully delineate the effectiveness 
of the TM group and to identify relevant variables influencing outcomes when using 
this format. 
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 Appendix A 
Lesson Plan 
Parkinson’s Speech Group 
Fall 2006 
Meeting: October 20, 2006 
Supervisor: Karen Haring 
Student Clinicians: Kiley Miller, Shannon Rogers, and Kristel Wilson 
Theme: Happy Halloween 
 
GREETINGS: 
1. State goals and agenda/theme for the day. 
• Goals- Use strong and precise speech 
                  THINK LOUD!! 
• Theme- Happy Halloween 
• Agenda- Warm-up, activities, homework, and cool-down exercises 
2. Discuss homework. 
 
WARM-UP 
1. “Do what I do” “Ah” for 5 seconds 
2. 15 “Ahs” for 5 seconds with 2nd clinician counting number of times 
3. Inhale; glide from a mid to high pitch; hold for 3 seconds 
4. Do 10 times with 2nd clinician counting number of times 
5. Inhale; glide from a mid to a low pitch; hold 3 seconds 
6. Do 10 times with 2nd clinician counting number of times 
7. Functional phrases; do 3 times; PowerPoint 
8. Functional sentences; do 3 times; PowerPoint  
 
ACTIVITIES 
During activities which allow any person to respond, we will go around the circle to 
ask individuals the questions for the activities. 
 
1. Hangman-a member of the group will pick a letter that they think might be 
in the word.  If they get the letter correct then we will add the letter to one 
of the blanks below the hangman.  If they do not get the letter correct then 
we will draw part of the hangman. 
2. Halloween Mix ‘n’ Match- There will be two columns of words (5 on each 
side) and when a group member puts the two correct words together we 
will draw a line connecting them together.  We will have the group repeat 
the word 2 times. 
 
Interim Energizer- Say “Ah” loudly and clearly for 5 seconds 5 times with 2nd 
clinician counting number of times 
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3. Crossword Puzzle-We will read the question to the group, and a member will 
try and guess what the answer is.  When the member gets the correct answer, 
then we will write it in on the crossword puzzle.  We will have the group 
repeat the answer 2 times. 
4. Ghost Bingo- We will supply the group members with bingo cards and candy 
corn to put on the spaces that we call.  We will first have the group repeat the 
word that we draw.  If an individual has that word, then they will repeat it 
alone in a longer phrase (e.g. I have a ghost).   
 
Interim Energizer- Say “Ah” loudly and clearly for 5 seconds 5 times with 2nd 
clinician counting number of times 
 
5.  Trivia-we will have 12 Halloween trivia questions for the group.  We will go 
around the circle to ask an individual if they know the answer.  We will have that 
individual say the answer, and then repeat it as a group 2 times.   
6.  Jokes- We will ask a group member if they know the answer to the joke.  Then 
we will repeat it 2 times as a group. 
7.  Superstitions-We will have a group member read the superstition and then 
repeat it as a group 1 time. 
 
DISCUSSION/CLOSING 
1. Questions???? Make sure everyone is comfortable with the homework 
procedure. 
2. Final energizer 
• Loud “Ah” 5 times for 5 seconds with 2nd clinician counting number of 
times 
• 10 functional phrases with 2nd clinician counting number of times 
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Appendix B 
Speaker Questionnaire: Pre-Therapy 
Please fill out this questionnaire to the best of your ability prior to the pre-
therapy voice recording that will be done the 1-2 weeks before the start of the 
group therapy. Be as specific as you can in your answers. Fill free to use the back 
of the form or another sheet of paper if you need more room. If you do not 
understand a question, one of the investigators (Either Jeff Searl or Karen 
Haring) will be available during the Pre-Therapy Voice Recording session to 
help you complete any unfinished portions of this questionnaire. 
 
Identifying Information 
 
Name:  ____________________________________  
 
Birth date: _____________      
 
Male   or    Female? 
 
Neurological and Other Medical Information 
 
Neurological Diagnosis/Stage: ____________________________________________  
 
Date of Initial Diagnosis: _________________ 
 
Date of when symptoms were first noted: ______________________ 
 
What were your initial symptoms of Parkinson disease or Parkinsonism? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
What are your current symptoms of Parkinson disease or Parkinsonism? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Do you have any tremor?  Yes ___  No ___  If yes, please describe: 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
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Do you have any other medical problems?  Yes ___ No ___ If yes, please describe:  
_____________________________________________________________________ 
 
Medication Information: 
 
Medication(s) for Parkinson disease:  
_____________________________________________________________________ 
 
How is it helpful? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Does your Parkinson medication affect your voice or speech?  Yes ___ No ___     
If yes, please describe: 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Do you experience “on/off” symptoms?  Yes ___ No ___ If yes, please describe: 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Do you experience dyskinesia:  Yes ___ No ___ If yes, please describe: 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Other medications and conditions for which they are taken: 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Surgical Information: 
 
Have you had neurosurgery (deep brain stimulator implant, pallidotomy, or other 
procedures) to help with your Parkinson disease? If yes, what procedure, when, 
where, by whom? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
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If you have had some type of neurosurgery, did it help with your Parkinson disease 
symptoms? If yes, please explain. Please specifically comment on whether your 
speech or voice was affected. 
___________________________________________________________ 
 
_____________________________________________________________________ 
 
Have you had any surgery on your larynx (or voice box)? If yes, explain what was 
done and why it was done. 
_____________________________________________________________________ 
 
If you have had surgery on your larynx, how was your voice/speech affected? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Speech Symptoms: 
 
Have you ever used your voice professionally (i.e., radio, television, acting, singing, 
etc.)?  Yes__ No__ If yes, please describe: 
_____________________________________________________________________ 
 
When did you first start to notice communication symptoms (i.e., changes in your 
speech and/or voice) that you associate with Parkinson disease?  
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
What are your current voice/speech symptoms? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
What is your most significant problem communicating today? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
How do you typically use your voice during the day? What types of activities do you 
do that require your voice? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
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How many hours of speaking do you do in a day? 
_____________________________________________________________________ 
 
Do people ask you to repeat? 
_____________________________________________________________________ 
 
What do you do when you want to be as easy to understand as possible?  
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
What percent of your speech do you think is intelligible (how much do people 
understand you)?  ____% 
Has Parkinson disease caused you to talk less? _________________  
How much less? ______________ 
 
Why has Parkinson disease caused you to talk less? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Do you think you run out of breath during speech? 
_____________________________________________________________________ 
 
Is it difficult for you to take a deep breath? 
_____________________________________________________________________ 
 
Have you noticed if your voice is monotone in pitch?  
_____________________________________________________________________ 
 
Is your speaking voice higher or lower in pitch compared to before your diagnosis of 
Parkinson disease? 
___________________________________________________________ 
 
Have you noticed pitch breaks in your voice? 
_____________________________________________________________________ 
 
Have you noticed changes in your singing voice? If yes, please describe. 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
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Have you noticed changes in the quality of your voice (i.e., is it hoarse, breathy, etc.)? 
If yes, please describe the changes you have noticed in quality.  
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Have you noticed changes in the steadiness of your voice? 
_____________________________________________________________________ 
 
Does your voice feel fatigued at the end of the day? 
_____________________________________________________________________ 
 
Have you noticed if your voice is reduced in loudness? 
_____________________________________________________________________ 
 
Have you noticed any slurring or mumbling in your speech? 
_____________________________________________________________________ 
 
Has the rate of your speech changed? Faster or slower? 
_____________________________________________________________________ 
 
Have you noticed any stuttering if your speech? 
_____________________________________________________________________ 
 
Do you think your voice sounds nasal? 
_____________________________________________________________________ 
 
Have you previously had speech treatment?  
_____________________________________________________________________ 
 
If yes, describe the treatment. How long ago did you have speech treatment? 
_____________________________________________________________________ 
 
How long were you in speech treatment (how many sessions, how many days/weeks, 
how long were the sessions)? 
_____________________________________________________________________ 
 
Was this done one-on-one or in a group therapy setting? 
_____________________________________________________________________ 
 
What types of things did you work on in the speech therapy? 
_____________________________________________________________________ 
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Was your previous speech treatment beneficial? Please explain. 
_____________________________________________________________________ 
     
_____________________________________________________________________ 
 
Swallowing Information: 
 
Have you noticed any problems with eating, chewing, and/or swallowing? 
_____________________________________________________________________ 
 
If yes, please describe (types of foods, frequency or problem, etc.) 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Have you noticed any change in taste or smell?  If yes, what type of change? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Neuropsychological Information 
 
Have you noticed any difficulty with your memory, problem solving, or ability to 
focus on a task? Please describe. 
_____________________________________________________________________ 
 
Does your medication affect your memory? If yes, how does it affect your memory? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
What aspect of your Parkinson disease bothers you the most?   
_____________________________________________________________________ 
 
_____________________________________________________________________
 Appendix C 
Voice Handicap Index (VHI) 
Name: ___________________________ 
Date: ____________________________ 
 
INSTRUCTIONS: These are statements that many people have used to describe 
their voices and the effects of their voices on their lives. Check the response that 
indicates how frequently you have the same experience. 
 
  Never Almost 
Never 
Sometimes Almost 
Always 
Always
1. My voice makes it difficult 
for people to hear me. 
     
2. I run out of air when I 
talk. 
     
3. People have difficulty 
understanding me in a 
noisy room. 
     
4. The sound of my voice 
varies throughout the day. 
     
5. My family has difficulty 
hearing me when I call 
them throughout the 
house. 
     
6. I use the phone less often 
than I would like. 
     
7. I’m teased when talking 
with others because of my 
voice. 
     
8. I tend to avoid groups of 
people because of my 
voice. 
     
9. People seem irritated with 
my voice. 
     
10. People ask, “What’s 
wrong with your voice?” 
     
11. I speak with friends, 
neighbors or relatives less 
often because of my voice. 
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  Never Almost 
Never 
Sometimes Almost 
Always 
Always
12. People ask me to repeat 
myself when speaking 
face-to-face. 
     
13. My voice sounds creaky 
and dry. 
     
14.  I feel as though I have to 
strain to produce voice. 
     
15. I find other people don’t 
understand my voice 
problem. 
     
16. My voice difficulties 
restrict my personal and 
social life. 
     
17. The clarity of my voice is 
unpredictable. 
     
18. I try to change my voice to 
sound different. 
     
19. I feel left out of 
conversations because of 
my voice. 
     
20. I use a great deal of effort 
to speak. 
     
21. My voice is worse in the 
evening. 
     
22. My voice problem causes 
me to lose income. 
     
23. My voice problem upsets 
me. 
     
24. I am less out-going 
because of my voice 
problem. 
     
25. My voice problem makes 
me feel handicapped. 
     
 
26. My voice “gives out” on 
me in the middle of 
speaking. 
     
27. I feel annoyed when people 
ask me to repeat. 
     
28. I feel embarrassed when 
people ask me to repeat. 
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  Never Almost
Never 
Sometimes Almost 
Always 
Always
29. My voice makes me feel 
incompetent. 
     
30. I’m ashamed of my voice 
problem. 
     
 
Please circle the word that matches how your voice feels today:       
 
Normal          Mild          Moderate          Severe 
 
 
P Scale __________     F Scale __________     E Scale __________     Total _______ 
 
 
 Jacobson, B.H., Johnson, A., Grywalski, C., Silbergleit, A., Jacobson, G., Benninger, 
M.S., et al. (1997). The Voice Handicap Index (VHI): Development and Validation. 
American Journal of Speech-Language Pathology, 6, 66-70. 
. 
 Appendix D 
Perceptual Rating Form - Speakers 
Name: ________________________ Date: ____________   
 
Please use a pen or pencil to mark the place on the line that best represents your 
typical speech: 
 
Always loud enough        Never loud  
_____________________________________________________________________ 
 
Never a “shaky” voice        Always a “shaky” voice 
_____________________________________________________________________ 
 
Never a hoarse “scratchy” voice              Always a hoarse “scratchy” voice 
_____________________________________________________________________ 
 
Never monotone       Always monotone 
_____________________________________________________________________ 
 
Never slurs                Always Slurs 
_____________________________________________________________________ 
 
Never a “strained” voice     Always a “strained” voice 
_____________________________________________________________________ 
 
Never mumbles         Always mumbles 
_____________________________________________________________________ 
 
Always speaks so others understand            Never speaks so others understand 
_____________________________________________________________________ 
 
Always participates in a conversation         Never participates in a conversation 
_____________________________________________________________________ 
 
Always starts a conversation              Never starts a conversation 
_____________________________________________________________________ 
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 Appendix E 
Speaker Questionnaire: Post-Therapy 
Please fill out this questionnaire to the best of your ability after the last group 
therapy meeting. Be as specific as you can in your answers. Fill free to use the 
back of the form or another sheet of paper if you need more room. If you do not 
understand a question, one of the investigators (Either Jeff Searl or Karen 
Haring) can help answer your questions (they can be reached at 913-588-5937).  
 
Identifying Information 
 
Name:  ____________________________________  
 
Birth date: _____________      
 
Male   or    Female? 
 
Voice and Speech Information 
 
Since you completed the group speech treatment, have you noticed changes in your 
speech and/or voice?  
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
If yes, please describe those changes. ______________________________________ 
 
_____________________________________________________________________ 
 
Have other people commented that it is easier to understand you now? 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
What have they said? ___________________________________________________ 
 
_____________________________________________________________________ 
 
Have people made any other comments regarding your voice, speech, or 
communication? Give examples of what they have said. 
_____________________________________________________________________ 
 
Do people ask you to repeat? ____________________________________________ 
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Do people have a hard time understanding you? ______________________________ 
 
What do you do when you want to be understood? ____________________________ 
 
_____________________________________________________________________ 
 
How often do you do that? _______________________________________________ 
 
Does it work? _________________________________________________________ 
 
Do you do more talking since you started or completed treatment? _______________ 
 
How much more? ______________________________________________________ 
 
Why? _______________________________________________________________ 
 
_____________________________________________________________________ 
 
What percent of your speech do you think is intelligible (i.e., people can understand 
you)? __________ 
 
Have you been practicing? _______________________________________________ 
 
How often? ___________________________________________________________ 
 
What do you do when you practice? _______________________________________ 
 
Does it help? _________________________________________________________ 
 
Medical Status and Medication 
 
Have you had any major medical changes since beginning the group speech therapy?  
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
Have you had any change in your medication since beginning the group speech 
therapy?  
_____________________________________________________________________ 
 
_____________________________________________________________________ 
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Your Thoughts on the Therapy 
 
What did you think was the main focus of the group speech therapy? (i.e., what was 
the therapy trying to get you to do?) _______________________________________ 
 
_____________________________________________________________________ 
 
Was the speech therapy program effective? _________________________________ 
 
What were your favorite things about the speech therapy program? _______________ 
 
_____________________________________________________________________ 
 
What did you not like about the speech therapy program? ______________________ 
 
_____________________________________________________________________ 
 
What changes would you recommend be made for the next time that the speech 
therapy program is offered? ______________________________________________ 
 
_____________________________________________________________________ 
 
